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ABSTRACT OF THE DISSERTATION 
DISCOVERY AND TARGETED MONITORING OF BIOMARKERS USING LIQUID 
CHROMATOGRAPHY, ION MOBILITY SPECTROMETRY, AND MASS 
SPECTROMETRY 
by 
Kendra J. Adams 
Florida International University, 2018 
Miami, Florida 
Professor Francisco Fernandez-Lima, Major Professor 
The complexity of biological matrices makes the detection and quantification of 
compounds of interest challenging. For successful targeted or untargeted identification of 
compounds within a biological environment, the use of complementary separation 
techniques is routinely required; in many situations, a single analytical technique is not 
sufficient. In the present dissertation, a multidimensional analytical technique was 
developed and evaluated, a combination of new sample preparation/extraction protocols, 
liquid chromatography, trapped ion mobility and mass spectrometry (e.g., LC-TIMS-MS 
and LC-TIMS-MS/MS). The performance of these techniques was evaluated for the 
detection of polybrominated diphenyl ethers metabolites, polychlorinated biphenyls 
metabolites in human plasma, opioid metabolites in human urine, and lipids in 
Dictyostelium discoideum cells. The new workflows and methods described in the body of 
this dissertation allows for rapid, selective, sensitive and high-resolution detection of 
biomarkers in biological matrices with increased confidence, sensitivity and shorter sample 
preparation and analysis time.  
 viii 
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1.1 Biomarker Monitoring 
The monitoring of biomarkers has become a necessary practice in several areas of human 
health research over the past decade, including: drug development1, cancer therapeutics2-3, 
disease monitoring4-5, and exposure assessment.6-7 Biomarkers are broadly defined as.8 
Major health and research organizations such as the FDA allow for the qualification of 
biomarkers for drug development, basic research and clinical practices.9 A wide variety of 
biomarkers exist, for example, there are genomic biomarkers, proteomic biomarkers or 
metabolomic biomarkers which originate from various biological processes and have the 
ability to reveal information based on a biological question or challenge. The chemical 
diversity of biomarkers makes their simultaneous detection, identification and 
measurement difficult within a single analytical acquisition. My dissertation focuses on the 
development of novel multidimensional analytical techniques for biomarkers in biological 
matrices.  
1.2 Analytical Techniques for Biomarker Monitoring 
Various analytical techniques can be utilized for biomarkers detection; they are constantly 
changing and developing as the advancement of technology continues. The combination of 
detection and separation techniques allows for a more comprehensive analytical approach 
for biomarker monitoring within complex matrices. 
1.2.1 Mass Spectrometry 
A relatively new technique for biomarker analysis includes the use of mass spectrometry 
(MS).10-11 Depending on the analytical need, a MS technique can exist to provide both 
qualitative and quantitative results including identification of targeted or untargeted 
compounds using the mass-to-charge (m/z) ratio of the ions analyzed.12-13 Mass 
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spectrometry is primarily used in proteomic research relating to the discovery and 
validation of biomarkers for cancer and other diseases.10 A targeted multiple reaction 
monitoring (MRM) approach has been defined as the standard of analysis for validation of 
biomarkers in complex matrices.14 Imaging mass spectrometry has been used for the 
identification, validation and spatial mapping of biomarkers within biological tissues for 
cancer diagnostics; imaging mass spectrometry allows for untargeted examination of a 
sample with the possibility of back-extraction of the data following initial analyses.15-16  
The ability to discover and validate biomarkers is afforded by mass spectrometry as the 
primary analytical technique. Although MS provides a large share of the data in typical 
biomarker analysis, working with biological matrices creates complications for the 
technique by itself. To optimize mass spectrometry methods for compounds in biological 
matrices, other analytical techniques, specifically separations, are used prior to, or in 
tandem with, MS. Separations using chromatography are widely popular for biomarker 
analysis, especially those involving proteomics. 
1.2.2 Chromatographic Separations  
Gas chromatography (GC) and liquid chromatography (LC) are separation techniques that 
depend on the retention of an analyte to a certain phase of media. Gas chromatography and 
LC have been coupled to MS for several years and have assisted in answering major 
biological questions.  
With the use of liquid chromatography, time is needed to flow solvents through a stationary 
phase and separate the compounds on the basis of a physical or chemical property such as 
size, polarity or hydrophobicity. Separation times needed in chromatographic procedures 
can vary depending on the application; from minutes (~5 min) for high throughput 
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methods17-18 to hours for certain lipid or protein applications.19 In addition to the time 
needed for these separations, there are other necessary items such as the proper column, 
(e.g., C18, monolithic, silica, C8, etc.) and the appropriate mobile phases for the separation 
and elution of, not only the compounds of interest, but also matrix interferences. Amounts 
and types of solvent also depend on the application LC is utilized for. Flow rates, 
temperatures and maximum pressures vary depending on the system being utilized. While 
liquid chromatography has provided baseline separations for compounds of similar mass 
and size; not all compounds can be separated by LC within the constraints of time and other 
resources needed. 
1.2.3 Ion Mobility Spectrometry 
In addition to chromatographic separations, ion mobility spectrometry (IMS) separations 
can be included for biomarker characterization and analysis. Ion mobility spectrometry 
allows for post-ionization separations in the gas phase and provides differentiation of 
molecules using their size and shape, or collisional cross section (CCS). Ion mobility 
spectrometry operates on a millisecond (ms) time scale and pairs well with 
chromatographic and mass spectrometric platforms. By combining IMS and 
chromatography, multiple dimensions of separation are achieved with the ability to couple 
with a variety of MS separation and detection techniques. A multi-dimensional separation 
allows multiple routes, not only for separations but also for identification of unknown and 
untargeted compounds. In contrast to LC, ion mobility separations occur in the gas phase 
and do not require the use of solvents. The CCS of a molecule is a physiochemical property 
which does not change with instrumental parameters unlike the retention time of a molecule 
in chromatography; an experimentally calculated CCS can be used as an identification 
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parameter, much like its m/z. A variety of IMS platforms have been developed to separate 
ions on the basis of different principles. Commercial ion mobility analyzers include 
platforms that operate using drift time (DTIMS), those that operate using ions travelling 
through a wave of changing voltages (TWIMS), ions separated on the basis of the 
differences in mobilities in high versus low-electric fields (FAIMS) or those based on the 
mobility of an ion moving through a ramp of electric field voltages and a flow of gas 
(TIMS).20-21 Each IMS instrument has advantages and disadvantages, including the ability 
to report accurate CCS values, the ability of simultaneous dual polarity analyses, its 
sensitivity, and the maximum resolving power achieved by the technique. The TIMS was 
pioneered in our research group in collaboration with Dr. Melvin A. Park and Dr. Mark E 
Ridgeway from Bruker Daltonics Inc. and its advantages will be demonstrated herein. The 
TIMS platform displays unrivaled sensitivity and resolving power and the ability to report 
CCS using first principles. Noteworthy is that the highest reported liner IMS resolving 
power is included as part of this dissertation (R ~ 400). 
1.3 Types of Biomarkers 
Compounds such as proteins, lipids and metabolites have proven helpful in following 
changes in a system after it has been subjected to an external disease or other stimulation. 
We know that biomolecules in a system change according to the health of that system but 
we are still working on what those changes mean and what types of changes are associated 
with which diseases and how biomarker monitoring can be used to diagnose and treat 
diseases rapidly and accurately. For the research included, the biomarkers analyzed will be 
broken down into two subclasses: exogenous and endogenous. 
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1.3.1 Exogenous Biomarkers 
There are thousands of compounds that can be considered exogenous biomarkers, or 
compounds that exist in an organism that are not naturally occurring, have entered the 
organism from the environment and can be related to a change in an organism. Exogenous 
biomarkers are typically analyzed in the field of exposomics, which refers to the study of 
the entirety of chemicals an individual has encountered throughout their lifetime. These 
compounds come from the external environment and the effects those compounds have on 
the individuals’ health are studied. A human’s exposome will fluctuate throughout their 
lifetime as a function of their location, diet and lifestyle choices. The study of exposomics 
is an “up-and-coming” –omics comparable to genomics, proteomics, metabolomics and 
lipidomics.22 
One major class of compounds that has been involved in the human exposome includes 
endocrine disrupting chemicals (EDCs), which are compounds that negatively impact the 
endocrine system. Polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls 
(PCBs) are two groups of EDCs that are discussed and analyzed in the subsequent research. 
Polychlorinated biphenyls and PBDEs are man-made compounds that were developed and 
used for consumer purposes such as flame-retardants for textiles and furniture, insulators 
in electric equipment, caulk, plasticizers in paints, and other plastic and rubber products.23 
Polybrominated diphenyl ethers were developed and used in the United States beginning 
in the 1970s and have been slowly and voluntarily phased out of production by their 
manufacturers beginning in the early 2000s.24 Polybrominated diphenyl ethers consist of 
groups of compounds with differing amounts of bromine atoms on diphenyl ether rings 
called congeners. Homologous, or isomeric compounds exist within each of the congener 
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groups and have the same chemical formula and mass spectrometric profile. In the US, 
there are three classes of PBDE congeners that have been commercially produced: 
pentabromodiphenyl ethers, octabromodiphenyl ethers and decabromodiphenyl ethers.23 
The PBDEs are not easily decomposed and, lower brominated congeners typically 
bioaccumulate in the environment and have been detected in water25-26, soil27-29 and aquatic 
species.30 In humans, PBDEs have been found in breast milk, blood and tissue 
Polybrominated diphenyl ethers are converted to hydroxylated-PBDEs (OH-PBDEs) 
through metabolism via oxidative pathways in human liver cells.31-34 
 Polychlorinated biphenyls were produced and used in the US from 1929 until 1979 
when they were banned from production due to the major negative health effects they have 
on humans.35-38 Like PBDEs, they exist as groups of congeners with a varying number of 
chlorine atoms attached to a biphenyl group. Polychlorinated biphenyls can be found across 
the world due to their robust nature and their ability to be streamlined into the water cycle 
and carried across oceans in both air and water medium. Polychlorinated biphenyls have 
been extensively studied for several decades and researchers have concluded that they are 
likely human carcinogens on the basis of animal and human exposure research.39-40 
Metabolism of PCBs to hydroxylated-PCBs (OH-PCBs) occurs via Cytochrome P-450 
with the location of the chlorines and the OH group posing a significant impact on the 
toxicity of the compound.36, 41-43  
Another example of exogenous compounds includes intentionally administered 
substances such as drugs. Although drugs are not technically considered biomarkers, for 
this research, they are used as a tool for the development of analytical methods for the 
detection and identification of compounds in human urine, which can be applied to 
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traditional biomarker analysis. A major concern across the US is the rising use and abuse 
of opioids.44-45 In this research, opioids are used as biomarkers for illicit and prescription 
pain management drug use. Drugs are considered part of the human exposome and reveal 
key facts about the human such as certain habits or locations they have been in.  
1.3.2 Endogenous Biomarkers 
Many naturally occurring compounds are considered useful biomarkers for detection and 
determination of causation of diseases. Compounds such as lipids, peptides, proteins, and 
DNA have been used as monitoring tools for various types of disease in humans and model 
organisms. In this work, lipids are the endogenous biomarker of choice for analysis. Lipids 
are fats involved in cell signaling, neurotransmissions and energy storage, and play an 
integral part of bilipid layered cell membranes. Lipids are a diverse class of molecules 
containing several categories including: fatty acyls (FA), glycerolipids (GL), 
glycerophospholipids (GP), sphingolipids (SP), sterol lipids (ST), prenol lipids (PR), 
saccharolipids, (SL) and polyketides (PK). Each lipid category differs on the basis of its 
“building-block”; whether it is derived from a ketoacyl or an isoprene group as well as its 
general structure and make-up.46-47 Lipid categories can be further broken-down into lipid 
subclasses, for example GPs are broken down into several subclasses, including: 
glycerophosphocholine (PC), glycerophosphoethanolamines (PE), glycerophosphoserine 
(PS), glycerophosphoglycerol (PG) and glycerophosphoinositol (PI). Lipids have served 
as biomarkers for various disease pathways or exposures such as, markers for air pollution6, 
Alzheimer’s Disease48-49, multiple sclerosis50, and many others.51 With such diversity in 
structure and size, method development for lipidomics analysis has become a popular topic 
for publications in recent years.52-54 Although much as been discovered regarding lipids in 
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biological structures, the research has been accomplished using several analytical methods 
to target different lipid classes and groups.51, 55 The future of lipidomic research lies in the 
development of an singular analytical method for complete lipid discovery, monitoring and 
quantitation.55-56 
1.4 Objectives of the Dissertation 
This dissertation is built on the development of new analytical workflows for the analysis 
of biomarkers in biological matrices. Six chapters are included beginning with the 
Introduction. Chapter Two, published in the International Journal for Ion Mobility 
Spectrometry 2016, Vol. 19 Issue 2-3, focuses on the analytical power of TIMS-MS for 
the separation of isomeric metabolites of endocrine disruptors. Chapter Three combines 
LC, TIMS and MS for separation and analysis of OH-PCBs in human blood plasma. 
Chapter Three was published in The International Journal of Mass Spectrometry and is 
currently available online. Chapter Four, currently accepted with minor revisions in 
Talanta, proposes a multidimensional LC-TIMS-MS approach for untargeted screening 
and quantitation of opioids in human urine. Chapter Five entails the surface analysis of 
lipids using TOF-SIMS with minimal sample volume and little preparation prior to 
analysis. Chapter Five was published in The Journal of Vacuum Science and Technology 
B, 2016 Volume 34, Issue 5. The final chapter included in this dissertation combines LC-
TIMS-MS/MS for lipidomic discovery and monitoring for the case of Dictyostelium 
discoideum cells at different biological stages. Chapter Six will be submitted to Analytical 
Chemistry for publication before the dissertation defense. 
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Abstract 
In this paper, high-resolution nano-electrospray ionization-trapped ion mobility 
spectrometry coupled to mass spectrometry (nESI-TIMS-MS) is used for the study of 
hydroxylated polybrominated diphenyl ether (OH-PBDE) metabolites. In particular, 
experimental ion-neutral collision cross sections (CCS) were measured for five structural 
OH-PBDE isomers using TIMS-MS. Candidate structures were proposed for each IMS 
band observed in good agreement with the experimental CCS measurements (5% error). 
The analytical power of TIMS-MS to baseline and partially separate structural isomers of 
OH-BDE in binary and ternary mixtures is shown for single charge species with a mobility 
resolving power of RIMS ~ 400. This work provides the proof of concept for the analysis of 
low concentration OH-PBDE in environmental samples based on accurate collision cross 
section and mass measurements without the need for derivatization and pre-fractionation 
protocols, thus significantly reducing the cost and analysis time. 
2.2 Introduction   
Polybrominated diphenyl ethers (PBDEs) are members of the brominated flame 
retardant family (BFR), which have been frequently added since the 1970s to commercial 
products (e.g., plastics and textiles).1 PBDEs are not chemically bound to the products and 
are easily released and accumulated in the environment, wildlife and humans.1-3 There are 
three major classes of PBDEs; PBDEs, methoxylated PBDEs (MeO-PBDEs) and 
hydroxylated PBDEs (OH-PBDEs). The former class is anthropogenically created and 
released into the environment from commercial production. Previous research has shown 
that both MeO- and OH-PBDEs are formed from two sources:they are naturally occurring 
and produced by alga or they are metabolites from commercially produced PBDEs that 
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have been released into the environment.4-6 Studies have shown that PBDE metabolites 
such as OH-PBDEs are more toxic than their PBDE counterparts.7-10 Differences in 
toxicity/activity of PBDEs and their metabolites have been noted based on the location of 
hydroxyl group and bromine atoms on the diphenyl rings.9-14 The variation in toxicity 
makes separation and identification of isomeric OH-PBDEs important for exposome 
profiling in the environment, humans and wildlife.  
Traditional methods such as gas chromatography-mass spectrometry (GC-MS) and 
liquid chromatography-mass spectrometry (LC-MS) have allowed for separation and 
identification of PBDEs and their metabolites. For example, previous studies have utilized 
GC-MS for profiling of PBDEs, OH-PBDEs and MeO-PBDEs in human breast milk and 
serum.15-17 In addition, GC-MS has been utilized for PBDE analysis in wildlife and 
environmental samples (e.g., different species of fish and various river sediment 
samples).17-18 The use of GC-MS for analysis of OH-PBDEs requires derivatiziation of the 
molecules to more volatile metabolites such as MeO-.15, 17, 19 Previously, Simpson et al. 
analyzed hydroxylated PBDE metabolites via GC-MS and COSMO-RS to determine 
experimental retention times and theoretical boiling points of the compounds. The 
COnductor-like Screening MOdel for Realistic Solvents (COSMO-RS) is a method that is 
used to calculate chemical potentials in liquids using the screening charge density.20-22 
Thermodynamic properties of molecules, such as boiling points, were predicted using 
COSMO-RS, converted to relative retention times and compared to experimental retention 
time values from GC-MS studies.19, 21-22 This research proved that OH-PBDE isomers 
could be separated via retention on a GC-MS column and unknown metabolites could be 
identified by the combination of theoretically calculated boiling points and experimentally 
19 
determined retention times after derivatization of the hydroxylated compounds.19 In 
addition, four out of the five OH-PBDE metabolites analyzed in this research have 
previously been extracted and identified from human serum based on GC-MS analysis.15 
Liquid chromatography-mass spectrometry (LC-MS) has also been used for both 
identification and quantification of PBDE metabolites within various matrices. Lacorte et 
al. developed an LC-ISP-MS/MS methodology in which eight different OH-PBDEs were 
identified and quantified from soil, fish and sludge.23 In these analyses, no sample 
derivatization was required, saving time and resources as well as allowing for the 
simultaneous analysis of both OH-PBDEs and MeO-PBDEs metabolites.23-25 LC-MS 
techniques have also been used to successfully analyze for similar metabolites, such as the 
chromatographic separation of 3-OH-BDE-47, 5-OH-BDE-47, and 6-OH-BDE-47 and the 
subsequent identification and confirmation via tandem mass spectrometry.24 Although both 
GC-MS and LC-MS have proven valid methods for analysis and quantification of OH-
PBDEs as standards and within biological matrices, the analyses still require a significant 
amount of time (i.e., chromatographic separations typically lasting 40 minutes) and 
derivatizing agents for GC-MS. 
Recent progress in gas-phase, post-ionization separations has been focused on the 
development of hyphenated techniques in order to achieve higher sensitivity, better 
separation and reduction of the chemical noise. Different variants of ion mobility 
spectrometry have been successfully coupled to mass spectrometry (e.g., periodic focusing 
DC ion guide,26-28 segmented quadrupole drift cell,29 multistage IMS,30-32 field asymmetric 
waveform IMS,33-34 travelling wave IMS,35 trapped ion mobility spectrometry,36-38 and 
cyclic drift tube mobility spectrometry.39-40 In particular, TIMS-MS has proved to provide 
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high mobility resolution separations (R~150-300)37, 41 and the measurement of accurate 
mobility values using first principles.37 TIMS-MS provides complementary information 
separating samples in two dimensions: size-to-charge and mass-to-charge separation on a 
very short time scale of analysis (hundreds of milliseconds).36-37 We have previously used 
TIMS-MS for detection of small molecules within complex matrices,42 the separation of 
polyaromatic hydrocarbons,43-44 targeted analysis of endocrine disruptors,45 and the 
analysis of the conformational dynamics of small molecules and biomolecules.41, 46-52 
In this paper, we explore the potential of TIMS-MS for the analysis of isomeric 
metabolites of PBDEs. Five OH-tetra-brominated diphenyl ethers are studied: 3-OH-BDE-
47, 5-OH-BDE-47, 6-OH-BDE-47, 4’-OH-BDE-49 and 2’-OH-BDE-68. Accurate 
mobility and ion-neutral CCSs were measured using nESI-TIMS-MS. Candidate structures 
were proposed for each IMS band observed of the individual OH-BDE. The capability of 
TIMS to separate structural isomers was evaluated for binary and ternary mixtures of OH-
BDE. This is the first time resolving powers of ~350-400 are reported for single charge 
species using TIMS-MS.  
2.3 Experimental Methods 
2.3.1 Material and reagents  
Hydroxylated tetra-brominated diphenyl ether standards were purchased from 
Accustandard Inc. (New Haven, CT, USA) and used as received.  Five OH-PBDEs were 
analyzed in this study:  3-OH-BDE-47, 5-OH-BDE-47, 6-OH-BDE-47, 4’-OH-BDE-49 
and 2’-OH-BDE-68. Binary and ternary mixtures were created by mixing equal volumes 
of individual standards and diluted to a final concentration of 200 nM. An aliquot (15μL) 
of each sample was deposited into a pulled glass capillary tip for nESI-TIMS-MS analysis. 
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All solvents used in these studies were analytical grade or better and purchased from Fisher 
Scientific (Pittsburg, PA). 
2.3.2 TIMS-MS Analysis 
TIMS-MS is a technique that combines size separation using ion mobility 
techniques and mass-to-charge separation via mass spectrometry allowing for ion 
identification.36-38 This separation technique is built on the utilization of an electric field to 
hold ions against a flow of gas which pushes ions toward the exit of the cell. The difference 
in pressure across the cell (P1>P2; where P1 is measured at the entrance and P2 is measured 
at the exit) dictates the velocity of the gas (N2) and subsequently ensures the ions 
consistently move toward the exit of the mobility region. A variation in voltage across the 
mobility region (low potential at the entrance and high potential at the exit) of the cell 
allows for the ions to be held in a place against the bath gas flow based on their size-to-
charge ratio.36-38 The mobility separation in a TIMS cell depends on the velocity of the bath 
gas, radial ion confinement (applied by an RF potential (measured as Vpp)) and ion elution 
parameters (ramp).36-38 The ions are successively eluted from the tunnel by decreasing the 
electric field in stepwise increments (referred as the “ramp”). The eluted ions are further 
separated by mass in a time-of-flight (TOF) mass spectrometer. The results provide both a 
mass spectrum of the sample and mobility values which are correlated to collisional cross 
sections to determine the size of the molecules.36-38, 53-57 The mobility in a TIMS analyzer 
can be described as:  
Ki=υg/Ex(i) A(1/(Vout-Velu(i))     (1) 
where υg is the velocity of the bath gas in the mobility cell and Ex(i) is the electric field at 
which the specific packet of ions elute. These parameters can be related to the voltage the 
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ions elute at (Velu(i)) and the voltage of the mobility region exit. The A value is a calibration 
constant that is experimentally determined using a standard of known mobility. From the 
K or mobility value, the collisional cross section (CCS) can be related by the following 
equation:  
𝐶𝐶𝑆 =
(18𝜋)
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The charge of the ion is represented by z, kb represents the Boltzman constant, m1 and mb 
are the masses of molecular ion and the bath gas and N* is the number density. 
The mobility resolving power for the analysis considered was calculated as  
𝑅 = 𝐶𝐶𝑆/𝛥𝐶𝐶𝑆        (3) 
Collisional cross sections were calculated using Tunemix as a calibration standard. Details 
on the Tunemix structures (e.g., m/z = 322 K0 = 1.376 cm
2 V−1 s−1 and m/z = 622 K0 = 
1.013 cm2 V−1 s−1) can be found elsewhere.37, 58 The instrument was operated in wide and 
narrow mobility selection modes, depending on the analytical challenge. For wide range 
mobility analysis, the gas velocity was defined by the entrance and exit TIMS roughing 
impedance (P1 = 1.6 and P2 = 0.62 mbar) and a voltage ramp of 200 V with Vout = 60 V 
were used. For narrow mobility selection experiments (higher resolving power), the 
velocity of the gas was increased (P1= 3.2 and P2=1.4 mbar) and a voltages 10 V and 60 V 
were used for the ramp and Vout, respectively. A Vpp = 300 V and 880 kHz radiofrequency 
was kept constant for all the experiments and allowed for radial confinement of the ions 
within the TIMS analyzer.  For the nESI source, quartz glass capillaries (O.D.: 1.0 mm and 
I.D.: 0.70 mm) were pulled utilizing a P-2000 micropipette laser puller (Sutter Instruments, 
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Novato, CA) and loaded with 15 µL aliquot of each sample solution. A typical nESI source 
voltage of - 600-1200 V was applied.  
2.3.3 Theoretical Calculations 
A pool of candidate structures was proposed for each OH-BDE standard analyzed 
in the TIMS- MS experiments. Final structures were optimized at the DFT/B3LYP/6-
311G(d,p) level using Gaussian software.59 Vibrational frequencies were calculated to 
guarantee that the optimized structures correspond to actual minima in the energy space 
and zero-point energy corrections were applied to calculate the relative stability between 
the structures. Theoretical ion-neutral collision cross sections were calculated using 
MOBCAL 60-61 software for nitrogen as a bath gas at ca. 300K. Partial atomic charges were 
calculated using the Merz-Singh-Kollman scheme constrained to the molecular dipole 
moment.62-63 
2.4 Results and Discussion 
TIMS-MS analyses of individual OH-BDE standards including 3-OH-BDE-47, 5-
OH-BDE-47, 6-OH-BDE-47, 4’-OH-BDE-49 and 2’-OH-BDE-68 resulted in a single IMS 
band for each structural isomer. Analysis of the mass spectra revealed the expected isotopic 
pattern of a tetra-brominated compound for the deprotonated molecular ion [M-H]- (Figure 
2.2.1). Analysis of the IMS projections showed that all individual compounds have very 
similar experimental CCS values, ranging from 194.5-197.3 Å2 (Figure 2.1 and Table 
4.2.1). In particular, 2’-OH-BDE-68 has the smallest CCS (194.5 Å2) while 4’-OH-BDE-
49 has the largest CCS (197.3 Å2).  The 6’-OH-BDE-47 and 2’-OH-BDE-68 have very 
similar CCSs (194.7 Å2 and 194.5 Å2, respectively). In addition, 3-OH-BDE-47 and 5-OH-
BDE-47 also have very similar experimental CCS (196.0 and 196.6 Å2, respectively).  
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Candidate structures were proposed for each IMS band observed (see Figure 2.2.1). 
Inspection of the optimized structures at the DFT/B3LYP/6-311G(d,p) shows that OH-
BDE are near planar conformations, with a slight twist around the central oxygen atom, 
depending on the position of the Br atoms (ortho vs para positions) (Figure 2.2.1). A small 
error was observed between the theoretical and experimental CCS values (less than ±5%).  
This small error can be attributed to the fact that the MOBCAL program does not properly 
describe bromine atoms for the CCS calculations.60-61 
 
[M-H]- 
m/z 
Experimental Theoretical 
TIMS (Å2) TM (Å2) 
2'-OH-BDE-68  500.7834 194.5 192 
6-OH-BDE-47  500.7834 194.7 186 
3-OH-BDE-47  500.7834 196.0 188 
5-OH-BDE-47  500.7834 196.6 190 
4'-OH-BDE-49  500.7834 197.3 193 
Table 2.1: Experimental and theoretical CCSs for 2’-OH-BDE-68, 6-OH-BDE-47, 3-OH-
BDE-47, 5-OH-BDE-47 and 4’-OH-BDE-49 isomers. 
  
   
2
5
 
Figure 2.1. Typical mass spectra (left), IMS projections (middle) and candidate structures (right) of 2’-OH-BDE-68, 6-OH-BDE-
47, 3-OH-BDE-47, 5-OH-BDE-47 and 4’-OH-BDE-49 
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 Following analysis of individual OH-PBDE compounds, binary and ternary 
mixtures of OH-PBDE standards were analyzed in order to evaluate the potential of nESI-
TIMS-MS for the separation of isomeric mixtures of these compounds. The analysis of a 
binary mixture containing 2’-OH-BDE-68 and 3-OH-BDE-47 shows that these two 
isomers can be baseline resolved with a mobility resolving power of ~350 (Figure 2.2). 
Closer inspection shows that 3-OH-BDE-47 elutes from the mobility cell at a voltage of 
143 V and 2’-OH-BDE-68 elutes at a voltage of 141 V while the same isotopic pattern was 
observed in the m/z domain (Figure 2.2a). Conversion of the trapping voltage to CCS shows 
that the 3-OH-BDE-47 peak is centered at 196.0 Å2 while 2’-OH-BDE-68 is centered at 
194.7 Å2 (Figure 2.2b), which are in good agreement with the analysis of individual 
compounds (Figure 2.2.1). A binary mixture of 4’-OH-BDE-49 and 6-OH-BDE-47 was 
analyzed using the same instrumental conditions. The 2D-IMS-MS contour plot shows two 
mobility bands eluting from the cell at trapping voltages of 144 V and 142 V respectively 
with the same m/z profile corresponding to the isotopic distribution of tetra-brominated 
OH-BDEs (Figure 2.2c). Conversion of the trapping voltage to the CCS shows baseline 
separation of 4’-OH-BDE-49 centered at 197.3 Å2 and 6-OH-BDE-47 centered at 194.7 Å2 
with a resolving power of ~ 320-350 (Figure 2.2d). It should be noted that in both analyses 
the narrow range of the ramp voltage (10 V), the higher gas flow velocity and the slow 
ramp speed permitted the achievement of high resolving power. In addition, the rigidity of 
the OH-PBDE molecules in contrast with previously studied systems (e.g., peptides and 
proteins) utilizing TIMS allows for the observation of narrower IMS bands.  
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Figure 2.2: Typical 2D-IMS-MS contour and IMS projection plots for the binary mixture 
of 3-OH-BDE-47 and 2’-OH-BDE-68 (a) and b)) and the mixture of 6-OH-BDE-47 and 
4’-OH-BDE-47 (c) and d)).  
Ternary mixtures of OH-BDE compounds were also created and subsequently 
analyzed via nESI-TIMS-MS. A mixture of 3-OH-BDE-47, 5-OH-BDE-47 and 2’-OH-
BDE-68 showed baseline separation between 2’-OH-BDE-68 and 3-OH-BDE-47 
(CCS=194.5 Å2 and 196.0 Å2) with a resolving power of 320-400. The two BDE-47 
compounds in the mixture (3-OH-BDE-47 and 5-OH-BDE47) were only partially resolved; 
however, the IMS peak clearly shows a bimodal peak with two well defined centers that 
correlate to the CCS of the single standards (Figure 2.3a). A second ternary mixture 
containing 6-OH-BDE-47, 5-OH-BDE-47 and 4’-OH-BDE-49 was analyzed to further 
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evaluate TIMS-MS as a method to separate isomeric mixtures (Figure 2.3b). In this mixture 
the two metabolites from BDE-47 were baseline separated with a resolving power in the 
order of 350-400; however, the 4’-OH-BDE-49 and 5-OH-BDE-47 were only partially 
resolved with centers that correlate to the CCS of the single standards (197.4 Å2 and 
196.6 Å2, respectively).  
 
 
 
 
 
 
 
 
Figure 2.3: Typical IMS projection plots from the ternary mixture of 3-OH-BDE-47, 5-
OH-BDE-47 and 2’-OH-BDE-68 (a) and the mixture of 4’-OH-BDE-49, 5-OH-BDE-47 
and 6-OH-BDE-47 (b). 
 
2.5 Conclusions 
In this work we provide the framework for rapid isomer separation of hydroxylated 
polybrominated diphenyl ethers using nESI-TIMS-MS. During the analysis of five OH-
BDE standards, experimental CCS values were calculated using TuneMix as a mobility 
standard. Candidate structures were proposed for all the IMS bands observed in good 
agreement with the experimental CCS (within ±5%). Analysis of binary mixtures showed 
that baseline separation is possible between 2’-OH-BDE-68 and 3-OH-BDE-47, 6-OH-
BDE-47 and 4’-OH-BDE-49, and 6- OH-BDE-47 and 5-OH-BDE-47 with a resolving 
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power of 350-400. Moreover, 3-OH-BDE-47 and 5-OH-BDE-47, and 5-OH-BDE-47 and 
4’-OH-BDE-49 isomers were only partially resolved. This work provides the foundation 
for the analysis of OH-BDE from complex mixtures utilizing small volumes (15 μL), 
significantly decreasing the amount of material necessary for the analysis without the need 
for derivatization or chromatographic separation. In addition, separation in the TIMS cell 
occurred on the millisecond range and experiments typically take less than 5 minutes per 
sample significantly decreasing the amount of analysis time when compared to GC-MS 
and LC-MS analyses. It should be noted that the TIMS-MS operation (as low as 50ms 
analysis time37) can be easily coupled to GC and LC pre-separation as a way to diminish 
the matrix effects during nESI for the analysis of complex mixtures. 
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Discovery and Targeted Monitoring of Polychlorinated Biphenyl Metabolites in 
Blood Plasma using LC-TIMS-TOF MS 
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3.1 Abstract 
In the present work, the potential for rapid, targeted analysis of hydroxylated 
metabolites of polychlorinated biphenyls (OH-PCBs) in diluted human blood plasma using 
liquid chromatography coupled with trapped ion mobility spectrometry and time-of-flight 
high resolution mass spectrometry (LC-TIMS-TOF MS) was evaluated. Experimental OH-
PCB collisional cross section (CCSN2) and gas-phase candidate structures (<3% error) are 
reported for the first time and used, in addition to the LC retention time and accurate m/z, 
as OH-PCB identification features to increase the detection selectivity. The proposed LC-
TIMS-TOF MS workflow combines a “dilute-and-shoot” sample preparation strategy, a 
robust liquid chromatography step, a high-resolving power mobility separation (R~150) 
and high-resolution mass spectrometry (R~30-40k) for the separation, identification and 
quantification of common OH-PCB isomers with limits of detection comparable to 
traditional workflows (e.g., LOD and LOQ of ~10 pg/mL and ~50 pg/mL, respectively). 
The high selectivity and low detection limits provide multiple advantages compared to 
current methodologies that typically require long, labor-intensive preparation and/or 
derivatization steps prior to gas or liquid chromatography-mass spectrometry. 
3.2 Introduction 
Polychlorinated biphenyls (PCBs) are endocrine disruptors that have antagonistic 
effects on reproductive, neurological, and immune systems in humans and wildlife.1 
Production of PCBs was banned in the United States during the 1970’s; however, these 
compounds are still found in the environment and considered persistent organic 
pollutants.2-4 PCBs are metabolized to hydroxylated PCBs (OH-PCBs) and/or methyl 
sulfone PCBs (MeSO-PCBs) via cytochrome P-450.3 Hydroxylation occurs through 
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epoxidation, which forms an arene oxide intermediate followed by the formation of a 
hydroxyl-PCB.3, 5-9 The location of the hydroxyl group on the biphenyl rings is directly 
correlated to the toxicity of analyte.1, 10 When the hydroxylation occurs at para- or meta- 
positions in combination with an adjacent chlorine atom, the compound bears significant 
resemblance to the thyroid hormones triiodothyronine (T3) and thyroxine (T4).11-12 The 
OH-PCBs competitively bind to the thyroid hormone receptors and can have up to 10-times 
higher binding affinity to transthyretin than the hormones themselves.5, 11-12 This 
competitive binding causes a high retention of OH-PCBs in blood plasma, resulting in 
various toxicological effects such as neurodevelopmental, reproductive impairment and 
carcinogenicity.5, 9, 13 
The most common experimental methods for the separation and detection of PCB 
metabolites are gas chromatography and liquid chromatography coupled to mass 
spectrometry (GC-MS and LC-MS). Traditionally, GC-MS analysis has been utilized for 
PCB metabolites, although, to analyze phenolic compounds, derivatization is required.7, 14-
16 Other studies have proposed the use of LC-MS/MS strategies for separation, detection, 
and quantification of OH-PCBs in humans and wildlife.7-8, 15, 17-18 Typically, before 
introducing the sample to a LC-MS system, an analyte extraction and sample cleanup 
protocol is required. Several methods of extraction have been utilized for various biological 
matrices such as whole blood, serum and plasma, most of which include liquid-liquid 
extraction followed by partitioning.18 Cleanup procedures have also been implemented 
using silica columns.18 After the lengthy extraction and cleanup steps for biological 
samples, a secondary cleanup is typically performed using solid phase extraction 
immediately prior to separation in the analytical column.8 The addition of these extraction 
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and cleanup procedures significantly increases the analysis time and typically require the 
use of added resources throughout the analytical procedure. Despite the progress made over 
the years, there is a clear need for simplified analytical workflows with enhanced 
selectivity and increased sensitivity.  
An alternative approach includes the use of gas-phase, post-ionization separations 
such as ion mobility spectrometry coupled to mass spectrometry (IMS-MS), which 
promises further gains in the speed, sensitivity and selectivity for the analysis of complex 
biological mixtures.19-20 Specifically, the added mobility dimension of separation yields an 
increase in peak coverage,21-24 a factor that has often inhibited the analysis of complex 
mixtures with MS-only detection. The ion’s mobility gives information on its size and 
shape via the momentum transfer ion-neutral collision cross section (CCS).25 While this 
description holds true for most contemporary IMS analyzers (e.g., periodic focusing DC 
ion guide,26-28 segmented quadrupole drift cell,29 multistage IMS,30-32 transient wave ion 
guide,33-34 and SLIM devices35), a common pursuit has been to increase IMS resolving 
power and ion transmission. 36-44 Since the introduction of TIMS-MS in 2011,45-46 our 
group,47-60 and others,61-70 have shown the potential of TIMS-MS for gas-phase separation 
and for molecular structural elucidation. In particular, we have demonstrated the 
advantages of TIMS for screening47 and targeted48 analysis of molecular ions from 
complex chemical mixtures; the study of isomerization kinetics of small molecules,49, 51-52 
peptides,50 DNA,59 proteins,54-55 DNA-protein complexes and protein-protein complexes 
in their native and denatured states.58 In a more recent report, we showed the isomer 
separation of polybrominated diphenyl ether metabolites using nanoESI-TIMS-TOF MS 
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with mobility resolving powers of up to 400 (the highest reported mobility resolving power 
for singly charged species).56  
In the present work, the potential for rapid, targeted analysis of hydroxylated 
metabolites of polychlorinated biphenyls (OH-PCB) using online liquid chromatography 
in tandem with trapped ion mobility spectrometry and TOF mass spectrometry (LC-TIMS-
TOF MS) was studied for the first time. Several OH-PCB congeners, ranging from penta-
chlorinated to hepta-chlorinated biphenyls, were studied as single standards, as mixtures 
and in the presence of a complex matrix-human blood plasma. The advantages of LC-
TIMS-TOF MS over traditional GC-MS and LC-MS/MS analysis are discussed based on 
analysis time, selectivity and sensitivity. 
3.3 Experimental Methods 
3.3.1 Materials and Reagents  
All solvents were purchased from Fisher Scientific (Pittsburg, PA) and were of LC-MS 
quality or better. Hydroxylated polychlorinated biphenyl standards were purchased from 
Wellington Laboratories (ON, Canada) and Accustandard, Inc. (New Haven, CT, USA). 
Pooled human plasma was purchased from Innovative Research (Novi, MI, USA). Nine 
OH-PCBs were used in this study: 2,3,3’,4’,5-Pentachloro-4-biphenylol (4-OH CB 107), 
2’,3,3’,4’,5-Pentachloro-4-biphenylol (4-OH CB 108), and 2,3’,4,4’,5-Pentachloro-3-
biphenylol (3-OH CB 118), 2,2’,3,3’,4’,5-Hexachloro-4-biphenylol (4-OH CB 130), 
2,2’,3’,4,4’,5-Hexachloro-3-biphenylol (3-OH CB 138), and 2,2’,3,4’,5,5’-Hexachloro-4-
biphenylol (4-OH CB 146), 2,2’,3,3’,4’,5,5’-Heptachloro-4-biphenylol (4-OH-PCB 172), 
2,2’,3’,4,4’,5,5’-Heptachloro-3-biphenylol (3-OH CB 180), and 2,2’,3,4’,5,5’,6-
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Heptachloro-4-biphenylol (4-OH CB 187). Binary isomer mixtures were created by mixing 
equal volumes of the individual standards.  
3.3.2 OH-PCB Human Blood Plasma Samples 
Pooled human plasma was removed from storage at -20° C and thawed to room 
temperature. A 150 μL aliquot of plasma was mixed with an equal amount of acetonitrile 
and spiked with a mixture of OH-PCBs for final concentrations of 0, 10, 25, 50, 100, 500, 
1000, 5000, and 10000 pg/mL. It has been reported that acetonitrile would break the cell 
membranes, as well as precipitate the large proteins as a way to increase extraction of the 
intracellular components.71-72 Three OH-PCB standards were used for the spike mixture: 
4-Hydroxy-2’,3,3’,4’,5’-pentachlorobiphenyl, 5-Hydroxy-2,2’,3,4,4’,5’-
hexachlorobiphenyl and 4’-Hydroxy-2,2’,3,3’,4,5,5’-heptachlorobiphenyl. Samples were 
vortex mixed for 1 minute and centrifuged at 4 oC for 10 minutes at 4500 rpm to remove 
the proteins from the aqueous layer. Following centrifugation, the supernatant was 
transferred, without any further clean-up, to LC vials with borosilicate glass inserts for 
analysis.  
3.3.3 LC-ESI- TIMS-MS Analysis  
The LC-ESI-TIMS-TOF MS analysis was performed using a custom-built TIMS-
TOF MS based on the maXis impact Q-ToF MS (Bruker Daltonics Inc, Billerica, MA). 
Sample injection (40 L) and LC separation was performed on a Shimadzu Prominence 
HPLC system consisting of two 20AD pumps, a SIL-20AC auto-sampler and a CTO 20-A 
column oven held at 40° C (Kyoto, Japan). An Onyx Monolithic C18 HPLC column (100 
x 4.6 mm) was used protected by an Onyx guard column (5 x 4.6 mm), both from 
Phenomenex (Torrance, CA, USA). A 15-minute gradient separation was performed at a 
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variable flow rate (2 mL/min for two minutes and then decreased to 1 mL/min for the 
remaining 13 minutes of the program) using water and acetonitrile. Mobile phase 
composition was changed as follows: hold 10% B for two minutes; increase to 97% B in 
three minutes and hold for 6.75 minutes; return to 10% B in 0.5 min and hold for 2.75 min 
for re-equilibration.  Samples were ionized and introduced into the TIMS-TOF-MS using 
an ionBooster ESI source in negative ion mode (Bruker Daltonics Inc, Billerica, MA). 
Typical ionBooster operating conditions were 1000 V capillary voltage, 400 V end plate 
offset, 300 V charging voltage, 4.1 bar nebulizer pressure, 3.0 l/min dry gas, 270 oC dry 
heater, and 400 oC APCI heater. 
A detailed overview of the TIMS analyzer and its operation can be found elsewhere. 45-46, 
53 The nitrogen bath gas flow is defined by the pressure difference between entrance funnel 
P1 = 2.7 mbar and the exit funnel P2 = 1.1 mbar at ca. 300 K. The TIMS analyzer is 
comprised of three regions: an entrance funnel, analyzer tunnel (46 mm axial length), and 
exit funnel. A 2040 kHz and 250 Vpp RF potential was applied to each section creating a 
dipolar field in the funnel regions and a quadrupolar field inside the tunnel. During TIMS 
operation, multiple ion species are trapped simultaneously at different E values resulting 
from a voltage gradient applied across the TIMS tunnel. After thermalization, species are 
eluted from the TIMS cell by decreasing the electric field in stepwise decrements (referred 
to as the “ramp”). The TIMS cell was operated using a fill/ramp sequence of 10/100ms or 
100/100ms for a 10% and 50% duty cycle for better chromatography and higher sensitivity, 
respectively. The TOF analyzer was operated at 10 kHz (m/z 100-1500). The data was 
segmented in LC frames over 10 analysis cycles yielding an LC-TIMS-TOF MS step size 
of ~2 s. Mobility calibration was performed using the Tuning Mix calibration standard 
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(G24221A, Agilent Technologies, Santa Clara, CA) in positive ion mode (e.g., m/z 322, 
K0 = 1.376 cm
2 V-1 s-1 and m/z 622, K0 = 1.013 cm
2 V-1 s-1) resulting in A = 231.064 for 
the instrumental and method conditions employed.53  The TIMS operation was controlled 
using in-house software, written in National Instruments Lab VIEW, and synchronized 
with the maXis Impact Q-ToF acquisition program.45 
Reduced mobility values (K0) were correlated with collisional cross section (Ω) using the 
equation: 
      (1) 
where z is the charge of the ion, kB is the Boltzmann constant, N
* is the number 
density of the bath gas, and mI and mb refer to the masses of the ion and bath gas, 
respectively.25 All resolving power (R=Ω/ΔΩ) values were determined from Gaussian peak 
fits after smoothing of peaks (Savitzky-Golay with 30-80 points of window) using 
OriginPro (version 8.0).  LC-TIMS-TOF MS data were processed using Data Analysis 
software v. 5.0 (Bruker Daltonics Inc, Billerica, MA) and the calibration plots utilized 
mobility selected data in the m/z domain.  
3.3.4 Theoretical calculations  
A pool of candidate structures were proposed for each OH-PCB analyzed using 
TIMS-TOF MS. Final structures were optimized at the DFT/B3LYP/6-311G(d,p) level 
using Gaussian software.73 Vibrational frequencies were calculated to guarantee that the 
optimized structures correspond to actual minima in the energy space, and zero-point 
energy corrections were applied to calculate the relative stability between the structures. 
Theoretical ion-neutral collision cross sections were calculated using iMOS74-75 software 
 
  *0
2/1
2/1
2/1
1111
16
18
NKmmTk
z
bB I 









 45 
for nitrogen as a bath gas at ca. 300K. Partial atomic charges were calculated using the 
Merz-Singh-Kollman scheme constrained to the molecular dipole moment.76-77 
3.4 Results and Discussion 
The TIMS-TOF MS analysis of the penta-chlorinated (4-OH CB 107, 4-OH CB 
108, and 3-OH CB 118), hexa-chlorinated (4-OH CB 130, 3-OH CB 138, and 4-OH CB 
146), and hepta-chlorinated (4-OH CB 172, 3-OH CB 180, and 4-OH CB 187) biphenyls 
is summarized in Figure 3.1 and Table 3.1. Inspection of the TIMS-TOF MS spectra 
showed the presence of deprotonated molecular ions [M-H]- with isotope patterns 
characteristics of compounds with five, six and seven chlorine atoms. Inspection of the 
corresponding mobility profiles for the single standards showed the presence of a single 
mobility band, with resolving powers of R~150. Experimental CCS are reported for all the 
analyzed single standards (Table 3.1). Inspection of Table 3.1 shows that there are very 
small CCS differences between the penta- (<0.4%), hexa- (<0.1%) and hepta- (<1.1%) 
chlorinated biphenyls. For example, the penta-CBs have an experimental CCS of 165.0 Å2, 
165.2 Å2 and 165.6 Å2 for the 4-OH CB 107, 4-OH CB 108 and 4-OH CB 118, respectively. 
Calculated CCS for the penta-CB proposed candidate structures show good agreement with 
the experimental CCS values (< 3% difference). The hexa-CBs have an experimental CCS 
of 170.0 Å2, 170.1 Å2 and 170.2 Å2 for the 4-OH CB 130, 3-OH CB 138 and 4-OH CB 
146, respectively. Calculated CCS for the hexa-CB proposed candidate structures show 
good agreement with the experimental CCS values (< 3% difference). The hepta-CBs have 
an experimental CCS of 172.6 Å2, 173.4 Å2 and 171.4 Å2 for the 4- OH CB 172, 3-OH CB 
180 and 4-OH CB 187, respectively. Calculated CCS values for the hepta-CB proposed 
candidate structures show good agreement with the experimental CCS (<2% difference). 
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Figure 3.1. Typical mobility profiles of single standards of penta-, hexa- and hepta-CBs 
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Name 
Chemical 
Formula 
Theoretical 
m/z [M-H]- 
Experimental 
m/z [M-H]- 
Error 
(ppm) 
Theoretical 
CCS (𝑨𝟐) 
Experimental 
CCS (𝑨𝟐) 
4 OH 107 C12H5Cl5O 
340.8681 340.8682 0.293 
161.3 165.0 
4 OH 108 C12H5Cl5O 161.2 165.2 
3 OH 118 C12H5Cl5O 161.1 165.6 
4 OH 130 C12H4Cl6O 
374.8291 374.8291 0.000 
164.1 170.0 
3 OH 138 C12H4Cl6O 165.0 170.1 
4 OH 146 C12H4Cl6O 166.0 170.2 
4 OH 172 C12H3Cl7O 
408.7901 408.7905 0.975 
171.0 172.6 
3 OH 180 C12H3Cl7O 171.0 173.4 
4 OH 187 C12H3Cl7O 171.3 171.4 
Table 3.1. List of experimental and theoretical m/z and CCS values for the penta-, hexa-, 
and hepta-CB considered in this study. 
 
When analyzed as binary mixtures, mobility separation was not observed between 
the penta-CBs (4-OH CB 107, 4-OH CB 108 and 3-OH CB 118) and hexa-CBs (4-OH CB 
130, 3-OH CB 138, and 4-OH CB146). We attribute these results to the similarity in CCS 
between the isomers (Table 3.1). The separation of these compounds is analytically 
challenging, and only attempts using SPE-LC-MS/MS has been shown to separate the 
penta-CBs 3-OH CB 118 to the 4-OH CB107/1088, 17 and the hexa-CBs 4-OH CB 130 to 
the 4-OH CB146/138.8, 17, 78 Moreover, baseline mobility separation was achieved for the 
case of the binary mixtures of the hepta-CBs with a mobility resolving power of R~150 for 
the case of 4-OH CB 187 and 4-OH-CB172/180; however, mobility separation was not 
observed for the case of 4-OH CB 172/180 (Figure 3.2). This mobility separation trend 
shows similarities with results observed using SPE-LC-MS/MS, where baseline separation 
is only observed between 4-OH CB 187 and 4-OH CB 172/180.8 
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Figure 3.2. Typical mobility profiles of the single standards and binary mixtures for the 
hepta-CBs. 
 
To reduce sample preparation steps and maximize throughput a “dilute-and-shoot” 
strategy was adopted. Previous studies for extraction of OH-PCBs from plasma involve the 
use of preliminary extraction and cleanup steps followed by lengthy chromatographic 
analyses.7-8, 15, 17, 79 The proposed method uses a quick clean-up step using acetonitrile to 
precipitate the proteins, followed by centrifugation. The supernatant is injected into the LC 
system, without further preparation, for three-dimensional separation in chromatographic, 
ion mobility and mass spectrometric domains.  The short LC method was developed using 
an Onyx Monolithic C18 column, which has been used previously, for direct plasma 
injections and thus was selected to account for minimal sample preparation and clean-up 
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prior to LC-TIMS-TOF MS analysis. The column output was combined with the 
ionBooster source, to allow high eluent flow-rates (~1 ml/min). In Figure 3.3, a two-
dimensional IMS-MS plot is shown for samples containing 2 ppb of a 9-component mixture 
of OH-PCBs in water (3a) and plasma (3b). The marked regions pertain to the penta-, hexa- 
and hepta-CBs (Figure 3.3). Inspection of the 2D-IMS-MS of the water sample shows clear 
mobility and mass separation of the penta-, hexa-, and hepta-CBs (Figure 3.3a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Typical 2D-IMS-MS contour maps of the penta-, hexa-, and hepta-CBs in water 
(a) and in human blood plasma (b). Note the separation of the PCB signals from potential 
interferences in the IMS-MS domain. 
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Inspection of the LC-TIMS-TOF MS data showed a two band chromatographic 
separation for the hexa- and hepta-CBs, and a single chromatographic band (RT=7.18 
minutes) for the penta-CBs. For example, the extracted ion chromatogram (EIC) for the 
hexa-CBs (m/z 374.8291) and the hepta-CBs (m/z 408.7905) showed the separation of 4-
OH CB 130 (RT=7.22 minutes) to the 4-OH CB 146/138 (RT=7.31 minutes) and 4-OH 
CB 187 (RT=7.26 minutes) to the 4-OH CB 172/180, respectively (RT=7.58 minutes). In 
the case of the plasma sample (Figure 3.3b), multiple peaks are observed in the 2D-IMS 
MS domain; moreover, a clear separation of the targeted CBs from the plasma signal is 
observed in the IMS-MS domain. That is, high selectivity can be achieved during CBs 
detection on the proposed LC-TIMS-TOF MS workflow. For example, the advantages for 
higher selectivity of the LC-TIMS-TOF MS workflow are shown for the case of the hepta-
CBs (Figure 3.4) combining LC separation with accurate CCS and m/z measurements. It 
should be noted, that the CBs CCS values can be used as universal parameters for routine 
identifications, specially, in the cases where single standards of CBs are not accessible.  
A comparative study of limit of detection (LOD) was conducted using traditional 
LC-ESI-TOF MS and the here proposed LC-ESI-TIMS-TOF MS for quantitative detection 
of OH-PCBs. The main purpose of the study was to assess the effect of the TIMS 
separation, while all other experimental parameters are kept constant (Figure 3.5). A nine-
point matrix-matched calibration curve was built with peak intensity as a function of 
analyte concentration. A linear response for the penta-, hexa- and hepta- CBs from 0-5000 
pg/mL was observed in both the LC-TOF MS and LC-TIMS-TOFMS analysis (R2>0.99). 
Differences in the response curve are related to the duty cycle during 
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Figure 3.4. Typical MS projection, LC projection and extracted ion mobility profiles for a 
mixture of  hepta-CBs, (OH-PCB 187, OH-PCB 180 and OH-PCB 172), from the LC-
TOF-MS analysis of the CBs in human blood plasma. 
 
the LC-TIMS-TOF MS measurements. That is, the use of single stage TIMS analyzer 
requires initial trapping followed by an elution step; during the elution step new ions are 
not introduced in the analyzer, which reduces the overall duty cycle. More recent version 
of the TIMS-TOF MS operate using a dual TIMS analyzer which allows for almost 100% 
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duty cycle.19 The limit of detection (LOD, defined as the concentration that produces a 
signal three times higher than the background noise) for LC-TIMS-TOF MS was 
established at ~10 pg/mL for penta-CBs, hexa-CBs and hepta-CBs (Figure 3.5). In contrast, 
the LOD for LC-TOF MS was obtained from the calibration plot at ~25 pg/mL, 2.5-times 
higher than the proposed technique (See Appendix 2). This highlights the ability of the LC-
TIMS-TOF MS to reduce the background interferences, cleaning up the detection of the 
targeted analytes during full scan detection (see Figure 3.3). The limit of quantification 
(LOQ, defined as the concentration 10-times higher than the background noise of the un-
spiked plasma) was established at 35 pg/mL for each analyte in spiked in plasma (Figure 
3.5), which is comparable to previous studies that employed GC and LC-MS/MS and 
reported LOQs between 1 and 100 pg/mL.8, 18, 78 In particular, Quinete et al.8 reported 
LOQs in the range of 20-50 pg/mL for the same analytes using a triple-quadrupole 
instrument to perform LC-MS/MS operating under multiple-reaction-monitoring (MRM) 
mode. The latter technique is considered the current standard for analytical quantitation but 
has the inherent disadvantage of focusing only on pre-programmed transitions that leave 
out any untargeted species. Therefore, our presented LC-TIMS-TOF MS technique offers 
similar sensitivity to triple-quadrupole instruments with the added benefit of detection of 
untargeted species, enhancing the value of the obtained data by enabling back-interrogation 
of analytes of interest that may arise in the future. This high sensitivity using a full-scan 
detection could be attributed to the very high selectivity of the LC-TIMS-MS approach, 
which provides with very low background levels thanks to the separation of the analytes 
from isobaric interferences contained in plasma (see Figure 3.3). 
 
   
5
3
 
 
Figure 3.5. Typical response curves for LC-TIMS-TOF MS as a function of a) penta- b) hexa- and c) hepta-CBs concentration in 
human blood plasma. Note the linear response for the penta-, hexa- and hepta- CBs from 0-5000 pg/mL in both the LC-TOF MS 
and LC-TIMS-TOFMS analysis.
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3.5 Conclusions 
This work demonstrated a rapid screening of OH-PCBs in diluted human plasma 
using LC coupled with tandem trapped ion mobility spectrometry and TOF mass 
spectrometry (LC-TIMS-TOF MS) detection. Experimental collisional cross sections and 
gas-phase candidate structures were reported for the first time for nine OH-PCB standards. 
The high mobility resolving power (R~150) of the TIMS analyzer permitted baseline 
separation of the hepta-CB 4-OH CB 187 and 4-OH-CB172/180, with differences in CCS 
of less 1%. Despite the high chemical complexity of human blood plasma samples 
(multiple peaks observed in the 2D-IMS MS domain during the analysis), a clear separation 
of the targeted CBs from other potential interferences is observed in the IMS-MS domain 
and used as quantitative signal with very high signal-to-noise ratios (LOD and LOQ of ~10 
pg/mL and ~35 pg/mL, respectively). The LC-TIMS-TOF MS performance is comparable 
to established techniques such as LC-MS/MS which, unlike this work, do not allow for 
untargeted analysis and back-interrogation of data. High throughput was achieved by 
limiting sample clean-up steps to protein precipitation followed by direct supernatant 
injection on a monolithic column for HPLC separation and tandem ion mobility/mass 
spectrometric detection. The superior performance of this simplified LC-TIMS-TOF MS 
analytical workflow removes the need for labor-intensive preparation steps to minimize 
chemical noise and represents a viable alternative to currently available methodologies. 
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4.1 Abstract 
In the present work, a fast separation, identification and quantification workflow based on 
liquid chromatography coupled to trapped ion mobility in tandem with mass spectrometry 
(LC-TIMS-MS) is described for the analysis of common isomeric drugs of abuse and their 
metabolites in human urine. In particular, the analytical performance of LC-TIMS-MS is 
shown for identification based on retention time, collision cross section and accurate mass 
for three sets of common isomeric opioids and their deuterated analogs in urine. The LC-
TIMS-MS analysis provided limits of detection of 1.4 - 35.2 ng/mL with demonstrated 
linearity up to 500 ng/mL, enabling discovery and targeted monitoring (DTM) of opioids 
in urine, with high precision in retention times (RT) (<0.3%), collision cross sections 
(CCS) (<0.6%) and mass accuracy (<1 ppm) across multiple measurements using external 
calibration. A good agreement was observed between theoretical and experimental CCS 
from candidate structures optimized at the DFT/B3LYP level. The need for complementary 
liquid and mobility separations prior to mass analysis is shown for the analysis of complex 
mixtures, with mobility resolving power of 80-130. The reproducibility and high speed of 
LC-TIMS-MS analysis provides a powerful platform for drug and metabolite screening in 
biological matrices with higher precision and confidence than traditional LC-multiple 
reaction monitoring (MRM) approaches. 
 4.2 Introduction 
An opioid epidemic has existed in the United States for almost twenty years; 
however, the rate of ongoing drug abuse continues to increase. Since 2000, deaths from 
drug overdose have virtually tripled and deaths involving opioids (including opioid 
painkillers and heroin) have increased nearly 200% 1. In 2015 ~62% of the ca. 50000 deaths 
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related to drug overdose are associated to opioid use, involving both illicit and legally 
prescribed drugs.2-5 This ever-increasing incidence of drug-related mortalities translates 
into a clear and present need for more sensitive techniques for drug detection and 
identification.6-7 Low therapeutic and abuse concentrations pose a challenge for screening 
and quantification of illicit drugs, analytical methods with high selectivity and sensitivity 
are need as monitoring tools for opioids to aid health care providers in their assessment for 
addiction treatment compliance and misuse. 8-9  
 Urine testing is a common first step when caring for opioid addicts or individuals 
using drugs for pain management purposes.10-13 Preliminary drug testing in urine typically 
includes the use of immunoassays, which provide qualitative results allowing the analyst 
to confirm the presence of broad drug classes.14-17 Although immunoassays provide rapid 
results, they typically fail to identify specific drugs types and lack sensitivity (cut-off 
concentrations ~300 ng/mL) and are also prone to cross-reactivity, increasing the 
possibility of false results.14-17 In comparison, liquid chromatography coupled to tandem 
mass spectrometry (LC-MS/MS) provides specific drug identifications based on retention 
time, intact mass and fragmentation patterns, and is becoming the gold standard for the 
detection of drugs of abuse and their metabolites in human fluids.14, 18-21 The use of LC-
MS/MS significantly decreases the rate of false results and is traditionally employed 
following a positive immunoassay test as a confirmatory tool.14, 16, 22-23 Identification, 
confirmation, and quantification of opioids in biological fluids, including urine and plasma, 
have been accomplished with LC-MS/MS, typically using triple-quadrupole instruments 
operating under multiple reaction monitoring (MRM) scan mode.9, 14-16 Chromatography 
methods range from 6-35 minutes in length and report cut-off concentrations, or limits of 
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detection (LODs) significantly lower than those of immunoassays ranging from 0.1 to 126 
ng/mL in urine. 14 
Ion mobility spectrometry coupled to mass spectrometry (IMS-MS) has been used 
for detection and separation of opioid compounds.18, 24-32 Previous studies have reported 
mobility values for codeine, morphine, normorphine, norcodeine, acetylcodeine, O6-
monoacetylmorphine, heroin and several other drugs using drift tube ion mobility 
spectrometers (DT-IMS).18, 25, 30, 32 In a more recent opioid analysis using high-field 
asymmetric wave-form ion mobility spectrometry (FAIMS), the separation of various 
isomeric opioids was shown with limits of detection (LODs) in urine for morphine and 
codeine of 60 ng/mL and 20 ng/mL, respectively.26, 28-29, 31 With the recent advent of higher 
resolving powers (R up to 400 33) and more sensitive ion mobility analyzers (e.g., Trapped 
Ion Mobility Spectrometers 34-36) there is a need to further develop complementary 
separations based on mass spectrometry for the study and characterization of complex 
biological samples. 37-39 In particular, liquid chromatography and trapped ion mobility 
separation techniques have proven useful for the analysis of single components in 
biological matrices.37 
 In the present study, for the first time, LC is coupled to TIMS in tandem with high 
resolution MS to provide a cohesive, multidimensional method to achieve high throughput 
analysis of isomeric opioids in urine. As a proof of concept, three sets of common isomeric 
opioids and their corresponding deuterated analogs are detected at trace levels in human 
urine after a “dilute-and-shoot” strategy. The compounds are identified based on their 
retention time, collisional cross section (CCS) and accurate mass, providing detection 
levels similar to those obtained with LC-MS/MS applications. With the additional 
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selectivity provided by the TIMS separation much higher selectivity is afforded (decreased 
false positives). In this method, because detection is not limited to a few MRM transitions 
the discovery of new targets or metabolites and/or data back-interrogation is enabled.  
 4.3 Experimental Methods 
4.3.1 Materials and Reagents  
All solvents were purchased from Fisher Scientific (Pittsburg, PA) and were of LC-
MS quality or better. Opioid compounds and deuterated standards were purchased from 
Cerilliant (Round Rock, TX). Eight opioid compounds and their deuterated analogs were 
analyzed: 6-acetylmorphine (A-009), 6-acetylmorphine-D3 (A-006), naloxone (N-004), 
naloxone-D5 (N-063), codeine (C-006), codeine-D6 (C-040), hydrocodone (H-003), 
hydrocodone-D3 (H-005), morphine (M-005), morphine-D3 (M-003), hydromorphone (H-
004), hydromorphone-D3 (H-006), norcodeine (N-005), norcodeine-D3 (N-082), 
norhydrocodone (N-053) and norhydrocodone-D3 (N-054). Human urine was purchased 
from Innovative Research (Novi, MI, USA) and supplied by opioid-free volunteers.  
4.3.2 Human Urine “dilute-and-shoot” Sample Preparation 
Calibration curves were prepared by adding a known amount of a mixture of the 
Cerilliant standards in human urine or water and spiking with 50 uL of deuterated internal 
standard (IS) mix. The curves consisted of seven calibration points ranging from 0.1 - 
500 ng/mL with a constant 50 ng/mL of deuterated IS mix. The spiked samples were 
diluted with water with 10% methanol for a final sample volume of 300 uL. No further 
extraction or preparation procedures were performed prior to analysis. Limits of detection 
(LODs) were determined using the linear regression method, where the lowest detectable 
signal is calculated from the intercept and standard error of the regression line calculated; 
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limits of quantification (LOQs) are reported as 5-times the LOD. Matrix effect experiments 
were performed using ten opioid-free urine samples spiked at low (75 ng/mL) and high 
(400 ng/mL) concentrations with 50 ng/mL of IS. Matrix effects were calculated by 
comparing the ratios of the spiked matrix samples to the average of six matrix -free water 
samples to obtain a matrix factor (MF).  
 4.3.3 LC- TIMS-MS Analysis  
The LC-TIMS-TOF MS analysis was performed using a custom-built TIMS-TOF 
MS based on the maXis impact Q-ToF MS (Bruker Daltonics Inc, Billerica, MA). Sample 
injection (50 L) and LC separation was performed on a Shimadzu Prominence HPLC 
system consisting of two 20AD pumps, a SIL-20AC auto-sampler and a CTO 20-A column 
oven held at 40° C (Kyoto, Japan). An Onyx Monolithic C18 HPLC column (100 x 4.6 
mm) was used protected by an Onyx guard column (5 x 4.6 mm), both from Phenomenex 
(Torrance, CA, USA). The mobile phase A composition consisted of 50 mM ammonium 
acetate in water and the mobile phase B consisted of 50 mM ammonium acetate in 96:4 
methanol:water v:v. Mobile phase composition was changed as follows: sample injection 
at 0% B and hold for 1.5 minutes. From 1.5 to 2.5 minutes increase to 99% B and hold 
until 4.25 minutes. Decrease to 0% B at 4.5 minutes and hold until 6 minutes for column 
re-equilibration at a flow rate of 2 mL/min.  
Samples were ionized using an ionBooster ESI source (Bruker Daltonics Inc, 
Billerica, MA) in positive ion mode. Typical ionBooster operating conditions were 1000 
V capillary voltage, 400 V end plate offset, 300 V charging voltage, 4.1 bar nebulizer 
pressure, 3.0 L/min dry gas, 250 oC dry heater, and 375 oC vaporizer. 
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A detailed overview of the TIMS analyzer and its operation can be found elsewhere 34-36. 
The nitrogen bath gas flow is defined by the pressure difference between entrance funnel 
P1 = 3.0 mbar and the exit funnel P2 = 0.9 mbar at ca. 300 K (see Figure S1). The TIMS 
separation depends on the gas flow velocity (vg), ramp voltage (Vramp), base voltage (Vout) 
and ramp time (tramp= number of steps x TOF time). The scan rate (Sr = ∆Vramp/tramp) is 
directly related to the resolving power of the TIMS analyzer.  
Each isomer emerges at a characteristic voltage (Velution): 
                K0 = vg/E  A/(Velution – Vout)              (1) 
where A is a calibration constant that can be determined using standards of known 
mobilities (i.e., Tuning Mix calibration standard m/z 322, K0 = 1.376 cm
2 V-1 s-1 and m/z 
622, K0 = 1.013 cm
2 V-1 s-1) 36. The TIMS cell was operated using a fill/ramp sequence of 
10ms/100ms for ~10% duty cycle and the TOF analyzer was operated at 10 kHz (m/z 100-
2500). Typical values were Vdeflector = 180, Vcapillary = 150, Vfunnel 1 in = 90V, Vramp = -175 - 
20, Vout = 60V, and a 250 Vpp at 880 kHz rf. A typical scan rate of Sr = 1.95 V/ms was 
used, or lower as needed to increase the mobility resolution. All voltages were controlled 
using custom software in LabView (National Instruments) synchronized with the MS 
platform controls. The data was segmented in LC frames over 10 analysis cycles yielding 
an LC-TIMS-TOF MS step size of ~2 s. The TIMS operation was controlled using in-house 
software, written in National Instruments Lab VIEW, and synchronized with the maXis 
Impact Q-ToF acquisition program 34. 
Reduced mobility values (K0) were correlated with collisional cross section (Ω) using the 
equation:   
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(2) 
 
where z is the charge of the ion, kB is the Boltzmann constant, N
* is the number density of 
the bath gas, and mI and mb refer to the masses of the ion and bath gas, respectively 
40. LC-
TIMS-TOF MS data were processed using Data Analysis software v. 5.0 (Bruker Daltonics 
Inc, Billerica, MA).  
 
Theoretical calculations  
A pool of candidate structures was proposed for all molecules of interest. Final 
structures were optimized at the DFT/B3LYP/6-311G(d,p) level using Gaussian 
software.41 Vibrational frequencies were calculated to guarantee that the optimized 
structures correspond to actual minima in the energy space, and zero-point energy 
corrections were applied to calculate the relative stability between the structures. 
Theoretical ion-neutral collision cross sections were calculated using MOBCAL42-43 
software for nitrogen as a bath gas at ca. 300K. Partial atomic charges were calculated 
using the Merz-Singh-Kollman scheme constrained to the molecular dipole moment 44-45 
  
4.4 Results and Discussion 
 Ion mobility profiles of isomeric opioid compounds (6-acetylmorphine (6-AM) and 
naloxone; codeine and hydrocodone; morphine, hydromorphone, norcodeine and 
norhydrocodone; and their respective deuterated analogs) show a single band for each of 
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the protonated molecules [M+H]+ (Figure 4.1) with small differences in ion-neutral 
collision cross section values in nitrogen (TIMSCCSN2): 6-AM and naloxone (176.7 and 
171.1 Å2, ~3%), codeine and hydrocodone (168.2 and 167.8 Å2, <1%) and morphine, 
hydromorphone, norcodeine, and norhydrocodone (162.9, 163.2, 167.9 and 167.4 Å2, <1-
3%) (see Table 4.1). These CCS values agree (Table 4.1) with theoretically calculated CCS 
(<5%) and previous studies that measured reduced mobilities using drift tube ion mobility 
spectrometry (DT-IMS).18, 24-25, 27, 32, 46 Upon review of the proposed candidate structures, 
visual similarities and differences in the size and shape, and, therefore, the theoretical CCS, 
are observed between opioid isomers (Figure 4.2). For example, major differences in the 
orientation of the nitrogen group as well as the methyl group on the oxygen atom are 
observed between 6-AM and naloxone (as highlighted in Figure 4.2). These differences are 
also observed in the measured experimental and theoretical CCS, which allow isomer 
separation, even at fast scanning rates (Table 4.1 and Figure 4.1). The candidate structures 
of codeine and hydrocodone, vary by the presence or absence of a carbonyl group on a six-
membered ring. This difference results in minimal changes in size; that is, the CCS values 
only slightly differ from each other (Figure 4.2). Morphine, hydromorphone, norcodeine 
and norhydrocodone differ in structure at the nitrogen, depending on whether a secondary 
(norcodeine and norhydrocodone) or tertiary amine (morphine and hydromorphone) is 
present in the compound. The difference in orientation of the amine group alters the 
theoretically calculated and experimentally measured CCS (Figure 4.2). Specifically, the 
similar amine group orientations of morphine and hydromorphone mean that the 
compounds cannot be separated based on CCS. Conversely, morphine/norcodeine and 
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hydromorphone/norhydrocodone have different amine orientations can be baseline 
separated in their mobility profiles (see Figures 4.2 and 4.3). 
Figure 4.1: Typical mobility profiles of analytes and their corresponding internal standards 
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Table 4.1: Experimental and theoretical m/z and CCS values for the opioid analytes considered. Note: values in parentheses refer to 
previously reported data from DT-IMSAir [18, 24, 26, 44-46] 
Name 
Chemical 
Formula 
Theoretical 
m/z [M+H]
+
 
Experimental 
m/z [M+H]
+
 
Error 
(ppm) 
Theoretical 
CCS (Å
2
) 
Experimental 
TIMS
CCSN2 (Å
2
) 
Experimental 
K0 (cm
2
V
-1
s
-1
) 
6-Acetylmorphine C19H21NO4 328.1543 328.1545 0.609 166.2 176.7 (167-171.1) 1.182 
6-Acetylmorphine-
D3 
C19H18D3NO4 331.1732 331.1733 0.302 166.3 176.9 1.189 
Naloxone C19H21NO4 328.1543 328.1542 0.305 166.7 171.1 1.221 
Naloxone-D5 C19H16D5NO4 333.1857 333.1855 0.600 166.6 171.0 1.229 
Codeine C18H21NO3 300.1594 300.1596 0.600 171.6 168.2 (168.9-178.9) 1.268 
Codeine-D6 C18H18D6NO3 306.1971 306.1969 0.653 171.7 168.0 1.256 
Hydrocodone C18H21NO3 300.1594 300.1592 0.666 171.8 167.8 1.271 
Hydrocodone-D3 C18H18D3NO3 303.1782 303.1783 0.330 171.7 167.9 1.257 
Morphine C17H19NO3 286.1438 286.1437 0.349 162.6 162.9 (172.8-189.0) 1.290 
Morphine-D3 C17H16D3NO3 289.1626 289.1625 0.346 162.4 164.0 1.289 
Hydromorphone C17H19NO3 286.1438 286.1437 0.349 161.6 163.2 (160.3) 1.287 
Hydromorphone-D3 C17H16D3NO3 289.1626 289.1625 0.692 161.5 164.4 1.286 
Norcodeine C17H19NO3 286.1438 286.1440 0.699 168.8 167.9 (196.1) 1.252 
Norcodeine-D3 C17H16D3NO3 289.1626 289.1625 0.346 168.9 167.9 1.259 
Norhydrocodone C17H19NO3 286.1438 286.1438 0.000 168.9 167.4 1.256 
Norhydrocodone-D3 C17H16D3NO3 289.1626 289.1625 0.692 168.9 168.0 1.259 
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Figure 4.2: Candidate structures optimized at the DFT/B3LYP/6-311G(d,p) of the opioids 
considered 
While mobility separation was observed using fast scan rates (Sr = 0.5-1.5 V/ms); 
it is noteworthy that baseline mobility separations are observed between 6-AM and 
naloxone, hydromorphone and norhydrocodone and morphine and norcodeine using slower 
scan rates (Sr = 0.2 V/ms) with resolving power in excess of 100 (see Figure 4.3). The 
ability to obtain baseline separation between these isomeric opioids can be attributed to the 
size and shape of the individual compounds, based the reported candidate structures (Figure 
4.2). Previous mobility analyses using drift tube IMS report resolving powers of about 70 
for codeine and morphine, which are not isomers.30 Despite the high resolving power of 
the TIMS analyzer, complete separation for all the isomers considered was not obtained 
(e.g., codeine and hydrocodone, morphine and hydromorphone, nor norcodeine and 
norhydrocodone), due to the marginal structural differences leading to minimal variations 
in CCS between these isomers (<1 Å2). Isomeric opioids that have previously separated 
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include: hydromorphone, morphine and norhydrocodone, via field asymmetric ion 
mobility spectrometry (FAIMS) MRM-MS28 and codeine and hydrocodone using a 
modified differential mobility spectrometry (DMS) cell.47  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Typical IMS separations of binary mixtures: top) 6-acetylmorphine and 
naloxone; middle) hydromorphone and norhydrocodone; bottom) morphine and 
norcodeine 
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The influence of matrix effects on the “dilute and shoot” LC-TIMS-MS workflow 
was studied by comparing the separation of opioid standards in water and in human urine. 
Inspection of the 2D-IMS-MS plots show a single trendline, containing the opioids as well 
as other potential interferences from the urine sample. Closer inspection of the opioid 
region reveals the separation of the opioid signals; however, potential molecular 
interferences from the urine may lead to higher limits of detection when compared to other 
IMS-MS-based DTM methods where the compounds of interest fall in a different trendline 
(data not shown).37 Moreover, the added advantage of liquid chromatography as a third 
dimension of separation allows for a clear separation of the potential matrix interferants as 
well as the separation of isomeric analytes that were not possible by TIMS-MS alone 
(Figure 4.4). The chromatographic program in this research had a final separation time of 
6 min which is comparable to the reported LC-MRM times (e.g., 6-35 min) for opioid 
analysis.14 Notice that the IS can be easily identified since they share the same retention 
time and CCS as their corresponding analyte. For example, naloxone and 6-AM can be 
separated by TIMS and by LC (retention times of 2.90 and 2.94 min, respectively). For 
quantification purposes, while the potential targets for naloxone and 6-AM isomers will 
have the same mass value, the IS of choice have different levels of deuteration so that they 
can be easily separated in the MS domain. That is, naloxone shows peaks at m/z 328.1542 
and 333.1857 corresponding to the [M+H]+ of the analyte and the IS [M(D5)+H]
+ 
containing five deuterium atoms. The mass spectrum for 6-AM contains two main peaks 
at m/z 328.1542 and 331.1730, corresponding to the analyte [M+H]+ and the IS 
[M(D3)+H]
+ with three deuterium atoms (Figure 4.4a). Codeine and hydrocodone are not 
separated in the mobility domain, yet there is near-baseline separation in the LC (2.92 and 
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2.97 minutes, respectively) (Figure 4.4b). Analogous to the naloxone and 6-AM 
quantification, the IS for codeine and hydrocodone are chosen with different amounts of 
deuterium so that they can be easily separated in the MS domain. Norcodeine and 
norhydrocodone are not separated in the mobility domain, yet there is near-baseline 
separation in the LC (2.91 and 2.97 min, respectively) (Figure 4.4c).  
 
Figure 4.4: Typical LC-TIMS-TOF MS analysis of isomeric opioids. 2D-IMS-MS contour 
plots are shown for the highlighted LC bands 
 
 Limits of detection (LODs) were compared between traditional two-dimensional 
separation (e.g., LC-TOF MS) and the currently proposed three-dimensional separation 
(e.g., LC-TIMS-TOF MS) for rapid and robust analysis of drugs of abuse and their 
metabolites. The LC-TOF MS and LC-TIMS-TOF MS results are summarized in Table 
4.2; noteworthy are the LC-TIMS-TOF MS LODs for the common opioids in human urine: 
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1.4-31.2 ng/mL using a DTM method. These results compare to reported LODs of 
0.6-2.5 ng/mL with 4-160 ng/mL linearity range using various extraction methods with 
MRM.14, 48-50 An increase in the LODs was generally observed in the presence of human 
urine which is consistent with increased background levels and/or decreased ionization 
yields associated with matrix effects.  The limits of quantitation (LOQs) range from 30.2-
156 ng/mL which are in agreement with reported LOQs of 0.1-126 ng/mL from single 
reaction monitoring (SRM) and MRM approaches.14, 48-50 
Evaluation of reproducibility and effect of chemical environment for three 
identification parameters (CCS, RT and m/z) is illustrated across the calibration levels 
analyzed (Figure 4.5). In the CCS domain, marginal deviations were observed between 
samples with and without urine (relative percent deviation, RPD, <0.5%). Additionally, 
CCS values did not change across calibration levels, suggesting that CCS is a valid 
parameter for analyte identification in the tested range and that this parameter could be a 
valuable addition to the traditionally used for qualitative analysis such as retention time 
(RT) and, when possible, accurate mass. In this case, RTs were minimally affected in the 
presence of urine (RPD of samples analyzed in urine compared to water were below 0.5%) 
and a high mass accuracy (<1 ppm) was observed for all analytes across calibration levels 
in the presence of urine. In addition, intra-day reproducibility is shown by small (<0.25%) 
percent relative standard (%RSD) for individual analytes in water and human urine across 
the seven calibration points (Table 4.3). These results demonstrate the reliability of this 
methodology for identifications in multiple dimensions using LC-TIMS-MS for 
quantitative analyses at the low ng/mL levels. During the performance of the matrix effect 
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experiments, no significant differences in the matrix factor (MF) of ten individual urine 
samples were observed for morphine, norhydromorphone, norcodeine, norhydrocodone, 
codeine and hydrocodone spiked at high (400 ng/mL) and low (75 ng/mL) concentrations 
(coefficient of variance, CV>15%) (See Figure S2). 
.  
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Table 4.2: Calibration results for analytes with (Matrix) and without urine (No Matrix) for LC-TIMS-qTOF MS and LC-qTOF MS
Analyte 
LC-TIMS-qTOF MS LC-qTOF MS 
Water Urine Water Urine 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
R2 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
R2 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
R2 
LOD 
(ng/mL) 
LOQ 
(ng/mL) 
R2 
Codeine 2.0 10.4 0.994 9.9 49.6 0.996 1.4 6.9 0.997 3.0 15.0 0.994 
Hydrocodone 3.0 15.1 0.994 6.0 30.2 0.996 1.8 9.1 0.997 7.6 38.2 0.995 
Morphine 7.9 39.5 0.996 27.9 138.6 0.993 7.9 39.5 0.996 31.9 159.4 0.999 
Norcodeine 8.3 41.6 0.997 31.2 156.0 0.999 7.4 37.3 0.997 35.2 176.0 0.999 
Norhydrocodone 8.1 40.4 0.995 29.1 145.8 0.996 8.1 40.7 0.996 20.7 103.5 0.996 
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Table 4.3: Intraday Variability of CCS and RT with and without urine represented by 
percent relative standard deviation (%RSD) 
 
 
 
 
 
 1 
Intraday 
Variability 
 RT (% RSD)  CCS (% RSD) 
Compound  Water Urine  Water Urine 
6-Acetylmorphine  0.07 0.04  0.18 0.22 
Naloxone  0.12 0.12  0.19 0.23 
Codeine  0.08 0.10  0.19 0.18 
Hydrocodone  0.08 0.10  0.22 0.27 
Norcodeine  0.09 0.07  0.22 0.21 
Norhydrocodone  0.05 0.07  0.20 0.22 
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Figure 4.5: Relative percent deviation of RT, CCS compared to non-matrix sample and δ 
m/z across calibration levels (*= no change) 
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4.5 Conclusions 
For the first time, liquid chromatography, trapped ion mobility spectrometry and mass 
spectrometry were combined for fast separation, identification and quantitation of opioids 
and their metabolites in human urine using a “dilute and shoot” approach. The proposed 
workflow provides analytical separation in the mobility and chromatographic domains 
within a 6 min analysis time, with LODs of 1.4 - 35.2 ng/mL with 0.5-500 ng/mL linearity 
range using DTM of opioids in urine. A good agreement was observed between the 
previously reported DTIMSCCS, measured TIMSCCS, and the theoretical CCS of the 
candidate structures for the familiar opioids optimized at the DFT/B3LYP level. Beside the 
higher confidence during LC-TIMS-TOF MS analyses, similar LODs and LOQs are 
reported to those obtained using traditional LC-MRM measurements, with small relative 
percent deviations in retention times (<0.3%), and collision cross sections (<0.6%) and 
high mass accuracy (<1ppm). The need for complementary liquid and mobility separations 
prior to mass analysis is shown for the analysis of complex mixtures, with a two-fold 
increase in mobility resolving power (R~ 80-130) compared to previous reports using DT-
IMS (R~50-70).  
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5.1 Abstract 
In the present work, the emission characteristics of lipids as a function of the primary ion 
cluster size and energy were studied using time-of-flight secondary ion mass spectrometry 
(TOF-SIMS). Characteristic fragmentation patterns for common lipids are described and 
changes in secondary ion (SI) yields using various primary ion beams are reported. In 
particular, emission characteristics were studied for pairs of small polyatomic and 
nanoparticle primary ion beams (e.g., Bi3
+ vs Ar1000
+ and Au3
+ vs Au400
+4) based on the 
secondary ion yield of characteristic fragment and intact molecular ions as a function of 
the lipid class.  Detailed descriptions of the fragmentation patterns is shown for positive 
and negative mode TOF-SIMS. Results demonstrate that the lipid structure largely dictates 
the spectral presence of molecular and/or fragment ions in each ionization mode due to the 
localization of the charge carrier (head group or fatty acid chain).  Our results suggest that 
the larger the energy per atom for small polyatomic projectiles (Bi3
+ and Au3
+), the larger 
the SI yield; in the case of nanoparticle projectiles, the SI increase with primary ion energy 
(200-500 keV range) for Au400
+4 and with the decrease of the energy per atom (10-40 
eV/atom range) for Arn=500-2000
+ clusters. Ion suppression due to matrix effects showed no 
correlation with the type of primary ion was observed. 
5.2 Introduction 
Secondary ion mass spectrometry (SIMS) is the gold standard for surface analysis of 
biological samples with submicron spatial resolution.1-6 Over the years, the primary ion 
beam of choice has changed as new ion sources have been developed and capabilities by 
application (e.g., organic vs inorganic surfaces) have been documented.7-9 For example, 
atomic and small polyatomic projectiles have shown distinct advantages for high spatial 
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resolution, while larger clusters and nanoparticle projectiles have shown enhanced 
molecular ion emission.7-8, 10-12 In addition, for the analysis of biological surfaces, the 
reduced damaged cross section of some nanoparticle projectiles (e.g., C60, argon and water 
clusters) has triggered recent developments for tridimensional biological imaging and 
profiling.7, 13-17 For example, a continuous Ar1000
+ beam provides a somewhat ‘softer’ 
desorption process which reduces the internal energy imparted to desorbed  molecules, 
resulting in significant improvements of molecular ion or pseudo-molecular ion yields. 
These types of molecular ions tend to be more diagnostic for structural characterization 
and identification of the biological systems from which they are generated.18 It has been 
reported that for an argon cluster beam, ideal ion yields are achieved when Eatom ≥ 10 eV 
and ion yields will quickly decline as the Eatom decreases.
15 It was also observed that when 
water molecules are used as primary ion beams, the optimal energy was about 3 eV/atom, 
which leads authors to believe further exploration into larger cluster projectiles is 
possible.15 During the study of peptides using various primary ion energies of an argon 
cluster it has been shown that larger peptide fragments were observed with lower energy 
beams as long as they were above 10 eV/atom; in addition, fragment intensity tends to 
decrease with increasing mass at 20 or 40 eV/atom.18 
Lipid profiling of biological samples is traditionally based on liquid extraction 
followed by liquid chromatography coupled to mass spectrometry (LC-MS/MS), with the 
collision induced dissociation spectra providing the necessary structural identification of 
the lipid class.19-21 Alternatively, we have recently shown that lipid identification can be 
performed using direct surface probe analysis (matrix-assisted laser desorption/ionization, 
MALDI), coupled to ultrahigh resolution mass spectrometry (Fourier transform ion 
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cyclotron resonance mass spectrometry, FT-ICR MS) followed by statistical analysis of 
variability and reproducibility across batches using internal standards.22 Lipid assignment 
from MS data can be performed utilizing the LIPIDMAPS database, where lipids are 
divided into eight major classes; fatty acyls (FA), glycerolipids (GL), glycerophospholipids 
(GP), sphingolipids (SP), sterol lipids (ST), prenol lipids (PR), saccharolipids (SL) and 
polyketides (PK).23-25 Analogous to MALDI probes, SIMS allows for in situ analysis of 
native biological surfaces, with higher spatial resolution. Due to the nature of molecular 
ion emission during SIMS analysis (not as soft as MALDI), fragmentation and intact 
molecular ion emission can be observed, with relative intensities varying with projectile 
size and energy. That is, the selection of the primary ion and energy determines the energy 
deposited per surface layer and the desorption volume, which corresponds to the 
observation of specific secondary ions.26-27 For example, during the analysis of lipid 
components from a biological surface, analyte specific fragment ions (lipid head groups 
and fatty acid fragments) are mainly observed under monoatomic and small polyatomic 
bombardment (e.g., In, Ga, Cs, Au3
+, Bi3
+, sources)28 while lipid molecular ions are 
increased under larger projectile bombardment (e.g., C60 and Au400
+4). In a comparison of 
40 keV C60
+ to 40 keV Ar4000
+ by Angerer and coworkers, it was observed that a majority 
of intact lipids from mouse brain were seen at higher secondary ion yields with the Ar4000
+ 
primary ion, that is the primary ion beam that provided the larger cluster size but lower 
Eatom.
29 This study also analyzed the signal of the pseudo-molecular ion of cholesterol 
[M+H-H2O]
+ using the aforementioned primary ion species and observed that similar 
secondary ion yields were detected for both of the projectiles, however, using Ar4000
+ a 
lower yield in the smaller lipid fragments was observed.29 
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In the present paper, we study the lipid specific molecular ion emission as a function 
of the primary ion characteristics utilizing time-of-flight, secondary ion mass spectrometry 
(TOF-SIMS). In particular, we revisit the molecular ion emission characteristics for two 
pairs of small polyatomic and nanoparticle primary ion beams (e.g., Bi3
+ vs Ar1000
+ and 
Au3
+ vs Au400
+4) using the secondary ion yield of fragment and intact molecular ions for 
familiar lipids. Emphasis is made on the relative distribution of lipid-specific fragment ions 
and molecular ions as a function of the projectile size and energy as well as the matrix 
effects on the ionization efficiency and secondary ion yields.  
5.3 Experimental 
5.3.1 Sample Preparation 
Lipid standards of sulfatides [131305, Brain, Porcine, (major component 18:1/24:1 
ST)], sphingomyelin [860061, Egg, Chicken (major component 18:1/16:0 SM)], 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine [850355, (16:0 PC DPPC)], 1-stearoyl-2-oleoyl-
sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) [840503, (18:0-18:1 PG)] and 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine [850745, (14:0 PE)] were purchased from 
Avanti Lipids Inc. (Alabaster, AL) and used as received. Each standard was dissolved in a 
dichloromethane: methanol (60:40) solution for a final concentration of 1 mg/mL each. 
Each standard was deposited onto an ITO slide (Sigma Aldrich, St. Louis, MO) by aerosol 
spray of 1 mL to guarantee surface homogeneity. The aerosol sprayer was washed with the 
same solvent solution in between spraying of individual standards. The samples were 
allowed to dry in a chemical hood prior to SIMS analysis. The same procedure was 
followed for the preparation of a mixture of lipid standards consisting of sulfatides, SM, 
DPPC, PE, and PG all equivolume with concentrations of 0.167 mg/mL.  
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5.3.2 SIMS Analysis 
Standards were analyzed using Bi3
+, Ar1000
+, Au3
+ and Au400
+4 primary ions in positive and 
negative ionization modes. A commercial IonTOF5 instrument (Chestnut Ridge, NY) 
containing a hybrid detector with a single microchannel plate, scintillator and 
photomultiplier was used for the 25 keV Bi3
+ and 20 keV Ar500-2000
+ analysis. The 25 keV 
Bi3
+ (0.12 pA) and 20 keV Ar1000
+ (0.04 pA) primary ion beams were rastered in sawtooth 
mode over a 250x250 μm2 field of view and mass spectra were collected for a total dose 
density of 2×1011 ions/cm2. Measurements were obtained in pulsed mode static SIMS at a 
frequency of 7.7 kHz.  The opening time of the second plate of the dual blanking plate has 
been reduced to obtain a lower beam current for Bi3
+ and subsequently avoid saturation of 
the detector. Secondary ion yields were normalized to the number of primary ions used to 
generate the mass spectral peak or total ion dose. A low energy flood gun is also utilized 
between pulses to ensure the sample surface remains neutral throughout the analysis. An 
internal calibration was performed using low mass ions and lipid head groups typically 
present in the sample: C2H3
+, C2H5
+, C3H7
+, C5H12N
+ and C5H14NO
+ in positive mode and 
CH-, CH2-, OH
-, CN- Cl-, CNO-, PO2
-, PO3
-, H2PO4, C4H10PO4
- in negative ion mode. For 
comparison of primary ion beam (Results and Discussion Section B), SI yield as a function 
of primary ion energy (Results and Discussion Section C) and SI yield as a function of 
chemical environment (Results and Discussion Section D), triplicate analyses were 
performed; error bars are calculated by the standard deviation between the SI yields of each 
replicate. The mass resolution of each primary ion beam was on average 1500 for Ar1000
+ 
and 4500 for Bi3
+ at m/z 400. For Au3
+ and Au400
+4 analysis, the primary ions were obtained 
from a 120 kV Pegase Platform,30-32 equipped with a gold liquid metal ion source capable 
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of producing a variety of projectiles (e.g., 150 nA for Au1
+, 15 nA for Au3
+ and 1 nA for 
Au400
+4 without beam collimation/pulsing at the target33). The primary ion projectiles were 
mass-selected using a Wien filter and focused into the TOF-SIMS analysis chambers. 
Negative mode TOF-SIMS was performed in the analysis chamber 1, where the target 
voltage is held at -10 kV (total acceleration voltage of up to 130 kV), whereas positive 
mode TOF-SIMS was performed in analysis chamber 2, where the target voltage is held at 
+10 kV (total acceleration voltage of up to 110 kV).33 Further information about the 
instrumental setup can be found in references.30-33 The average mass resolution for Au3
+ 
and Au400
+4 analysis at m/z 400 is 2000 and 450 in chamber 1 (equipped with a reflectron 
TOF) and in chamber 2 (equipped with a linear TOF), respectively. 
5.4 Results and Discussion 
5.4.1 Lipid Characterization by Class 
TOF-SIMS analysis can provide sufficient information to identify a lipid of a 
specific class based on the simultaneous detection of analyte specific fragment and intact 
molecular and/or pseudo-molecular ions (e.g. [M]+, [M+H]+, [M+Na]+, [M]- and [M-H]-). 
For example, phospholipids are a class of lipids that are predominantly abundant in 
biological membranes and consist of two fatty acids, glycerol, phosphate and an alcohol 
group. There are several subclasses of phospholipids which differ based on the alcohol 
moiety present in the molecule (i.e. serine, ethanolamine, choline, glycerol or inositol). In 
previous reports, various lipid species including intact lipids, head group fragments and 
fatty acyls have been identified in cell lines using several mass spectrometry techniques 
(e.g., ESI-MS/MS, DESI-MS/MS, MALDI-MS/MS and SIMS). DESI-MS/MS, MALDI-
MS/MS and SIMS have the advantage over traditional ESI-MS/MS in that lipid 
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identification may not require sample extraction protocols and direct analysis can be 
performed from the biological tissue of interest; while there are major differences between 
the ionization mechanism of DESI-MS/MS, MALDI-MS/MS and SIMS, all three 
techniques can provide spatial information with SIMS providing the highest spatial 
resolution. A tradeoff is that in the case of TOF-SIMS, the ratio of molecular to fragment 
ion and the spatial resolution significantly depends on the projectile size and energy as well 
as on the lipid species of interest and TOF-SIMS analysis mode (positive versus negative). 
For example, in positive mode TOF-SIMS head group fragments corresponding to the 
sphingomyelin and phosphatidylcholine are identified at m/z: 206 C5H14NPO4Na
+, 184 
C5H15NPO4
+, 104 C5H14NO
+ and 86 C5H12N
+ via TOF-SIMS, ESI-MS/MS (Figure 5.1a 
and 5.1b).1, 4, 34-41 Both of these lipid classes yield an internal fragment at m/z 125 in positive 
ionization mode arising from fragmentation of the head group to yield a cyclic C2H6PO4
+ 
fragment. 40, 42 Negative mode TOF-SIMS of sphingomyelin and phosphatidylcholine 
reveals two head group fragments at m/z 123 C2H4PO4
- and m/z 168 C4H11NPO4
-.43 Three 
larger fragments of higher mass are detected in sphingomyelin analysis related to the loss 
of methyl [M-CH3]
-, trimethylamine [M-C3H9N]
- and ethyltrimethylammonium [M-
C5H13N]
- groups from the head group of the lipid (Figure 5.1a and Appendix 4).4, 42 In 
addition, fragment ions corresponding to the carboxylic acid chain are typically detected 
from phosphatidylcholine only (see example in Figure 5.1b). Lipids in the sphingomyelin 
and phosphatidylcholine classes have the same head group and therefore cannot be 
differentiated from each other exclusively based on the head group fragment detection. 
There are few differences between the ionization of sphingomyelin and 
phosphatidylcholine by TOF-SIMS; the major difference is attributed to the head group 
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fragment at m/z 224 which is not observed in sphingomyelin.44-47 A second difference in 
the TOF-SIMS of PC versus SM is the presence of fatty acid fragments in the 
phosphatidylcholine lipid profile in negative mode, which are not observed in 
sphingomyelin (Figure 5.1a, 5.1b, and 5.2f). 
In addition to phosphatidylcholine and sphingomyelin, phosphatidylethanolamine 
and phosphatidylglycerol fragmentation patterns by TOF-SIMS analysis are described 
herein. Fragments observed in the phosphatidylethanolamine lipid class include, the 
internal fragments of m/z 125 C2H6PO4
+ and m/z 123 C2H4PO4
- in positive and negative 
mode, respectively. 40 A tail group fragment after the loss of the head group 
[M – C2H7NPO4]- and the loss of a fatty acid chain [M-FA Chain]- were detected (Figure 
5.1c and 5.2b). Two major characteristic fragments of phosphatidylethanolamine were 
detected at m/z 141 C2H8NPO4
+, and m/z 140 C2H7NPO4
- and m/z 196 C5H11NPO5
-43 in 
positive and negative TOF-SIMS modes, respectively, allowing for identification of the 
phosphatidylethanolamine class versus all other lipids considered in this study.  
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Figure 5.1. Fragmentation schemes of lipid standards of a) sphingomyelin b) 
phosphatidylcholine c) phosphatidylethanolamine and d) phosphatidylglycerol for positive 
(red) and negative (blue) mode TOF-SIMS analysis. 
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Figure 5.2. Typical TOF-SIMS mass spectra of familiar lipids in positive and negative 
mode. Characteristic fragment ions (*), fatty acid fragments and intact molecular ions are 
denoted in the spectra. 
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Analysis of phosphatidylglycerol in positive mode TOF-SIMS yields the cyclic head 
group fragment at m/z 125 C2H6PO4
+ as well as the sodiated form of that fragment ion at 
m/z 147 C2H6PO4Na
+.48 Fragments at m/z 171 C6H8PO6
- and m/z 152 C3H6PO5
- are 
characteristic fragments significant to the phosphatidylglycerol class in negative mode 
TOF-SIMS. A m/z 227 C6H12PO7
- is also observed corresponding to the loss of both fatty 
acid chains from the phosphatidylglycerol lipid in negative mode TOF SIMS (Figure 5.1d 
and 5.2c).49 The sulfatide class is typically analyzed in negative mode TOF-SIMS. 
Characteristic fragments are detected for the head group at m/z: 97 HSO4
-, 199 C4H7O7S
-, 
225 C6H9O7S
-, 257 C6H9O9S
-, 259 C6H11O9S
- and 300 C8H14NO9
-. All head group 
fragments are specific to the sulfatides due to the presence of a sulfur atom. A mixture of 
sulfatides with varying fatty acid composition results in the observation of a variety of 
intact molecular ions (Figure 5.2e and Appendix 6).  
Fatty acid chains are typically observed in negative mode TOF-SIMS in 
phosphatidylethanolamine, phosphatidylglycerol, phosphatidylcholine and sulfatides. For 
example, phosphatidylethanolamine and phosphatidylglycerol analysis show peaks at m/z 
227 C14H29O2
- and m/z 283 C18H35O
- corresponding to the 14:0 and 18:0 fatty acid chain 
fragments (Figure 5.1c and 5.2a). The sulfatide standard contains a mixture of lipids and 
fatty acids fragment peaks are observed in the mixture at m/z 255 (16:0), m/z 283 (18:0) 
and m/z 311 (20:0) (Figure 5.2e and Appendix 6). By combining the information obtained 
from the head group fragments, fragment fatty acid chains, tail group fragment, loss of a 
fatty acid chain, and the pseudo-molecular ions, it may be possible to directly correlate the 
TOF-SIMS spectral features to the lipid structure in complex biological matrices. The later 
 103 
analysis can be simplified further when using coincidence TOF-SIMS techniques during 
single ion bombardment.50 
5.4.2 SI Yield as a Function of the Projectile Size 
Lipid standards were analyzed as a function of the projectile size (Bi3
+ and Au3
+
, Ar1000
+ 
and Au400
+4) and energy. An increase in secondary ion yield (SI yield) was observed 
between small polyatomic and nanoparticle projectiles throughout all lipid classes in 
positive and negative ionization mode (see example for Bi3
+
 and Ar1000
+ in Figure 5.3). In 
the sulfatide class, over ten-fold increase is observed for 20 keV Ar1000
+ when compared to 
25 keV Bi3
+ in negative mode TOF-SIMS. The [M-H]- SI yields of the other lipids showed 
an increase when going from Bi3
+ to Ar1000
+ primary ions, but most of the changes were 
not as large as that seen in the ST class (Figure 5.3a). In the cases of sphingomyelin and 
phosphatidylethanolamine the SI yield of the [M-H]- molecular ion had less than an order 
of magnitude of change in abundance, whereas phosphatidylglycerol and 
phosphatidylcholine had a more significant abundance increase. Phosphatidylcholine had 
the second largest increase in SI yield when changing from Bi3
+ to Ar1000
+ primary ions. SI 
signal enhancements were previously reported for argon clusters relative to bismuth 
clusters for the analysis of biological molecules (diadenosine triphosphate and diadenosine 
tetraphosphate).51 In positive mode TOF-SIMS a different trend is observed for SI yield 
variation with the primary ion projectile size (see Figure 5.3b). The only protonated 
molecular ion showing significant differences in the SI yield corresponds to the 
sphingomyelin class. The remaining [M+H]+ molecular ions of the lipids do not show 
significant changes in SI yield using the two different primary ion beams. A variation 
between the SI yields of the intact lipid molecular ion ([M-H]-/[M+H]+) of each lipid class 
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is observed for both positive and negative mode TOF-SIMS; however, negative mode 
TOF-SIMS shows greater variation in the SI yields (Figure 5.3). The increase in SI yield 
with the Ar1000
+ beam can be attributed to the “softer” desorption regime compared to that 
of Bi3
+
. The Eatom for each beam is discussed in detail later; however, in the examples shown 
the Ar1000
+ beam has an energy per atom closest to that deemed the ideal 
(Eatom = 10 eV/atom).
15 
Figure 5.3. intact molecular ion si yield emission using small polyatomic bi3+ and 
nanoparticle ar1000+ primary ion projectiles for familiar lipid standards using tof-sims in 
a) negative and b) positive mode. 
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The comparison of SI yields of lipids using gold projectiles showed that the 
nanoparticle projectile Au400
+4 may provide over tenfold increase in the SI yield when 
compared to the small polyatomic projectile Au3
+
 (Appendix 7). For example, during 
sulfatide analysis the intact molecular ion (ST 40:1) showed a 100-fold increase in the 
secondary ion yield from 50 keV Au3
+ to 440 keV Au400
+4
 and a 10-fold increase for the 
smaller gold beam when compared to 25 keV Bi3
+ (Appendix 7). There is a 2-3 order of 
magnitude increase in the SI yield when using 440 keV Au400
+4 versus 20 keV Ar1000
+ that 
can be primarily attributed to the incident energy of the projectile (Appendix 7). Overall, 
the analysis of lipids using Au400
+4 followed the same trend with a two order of magnitude 
increase in SI yield compared to Au3
+ (Appendices 7 and 8).  SI yields of 440 keV Au400
+4 
were 2-3 orders of magnitude higher than those obtained using the Ar1000
+
 primary ion beam 
for most lipid classes (e.g., sphingomyelin, phosphatidylglycerol, phosphatidylcholine and 
phosphatidylethanolamine, see Appendix 7). It has been previously noted that the estimated 
Au3
+ SI yields would be equal to Bi3
+ yields because they are of similar nature and size.52 
For a more detailed analysis, the Eatom needs to be considered due to the large differences 
in energies used for each primary ion beam. For the small polyatomic projectiles, the Eatom 
are calculated at approximately 8000 eV and 16000 eV for Bi3
+ and Au3
+, respectively. Our 
results suggest that the larger the Eatom for small polyatomic projectiles, the larger the SI 
yield. A discussion of the SI yield as a function of the energy and cluster size is provided 
for the Arn=500-2000
+ and Au400
+4 nanoparticle projectiles.  
5.4.3 SI Yield as a Function of the Projectile Energy 
Previous work has shown that high energy, massive gold projectiles are 
advantageous for biological sample analysis and that the higher the cluster size the higher 
 106 
the SI yield.32 This correlates to data obtained by Vickerman et al. and by Yokoyama et al. 
where SI yields of both metals and organic substances increases with the primary ion 
impact energy (up to 120 keV for C60 projectiles), being most notable for higher mass 
fragments.53-54 Here, we further investigate the effect of the primary ion energy and size on 
the SI yield for the case of the phosphatidylglycerol (18:0-18:1 PG) lipid standard (see 
Figure 5.4). Two studies are carried out: i) the influence of the projectile energy on the SI 
yield for nanoparticle Au400
+4 projectiles, and ii) the influence of the projectile size on the 
SI yield for 20 keV Arn
+ (n = 500-2000 atoms) projectiles.  
In positive and negative mode TOF-SIMS, as the primary Au400
4+ ion energy 
increases, there is a net SI yield increase of molecular and fragment ions (Figure 5.4a and 
4c). For example, in negative mode TOF-SIMS closer inspection shows that small (m/z: 
153, 281 and 283) and larger (m/z 509 and 511) mass fragments show a slightly different 
increasing slope, being a steeper positive slope for the smaller fragments (see Appendix 9a 
and Appendix 8). Notice that analyte-specific fragment ions corresponds to the head group 
(m/z 153), fatty acid groups (m/z 281 and 283 for 18:1 and 18:0, respectively) and the loss 
of one fatty acid group (m/z 509 and 511). For the low mass fragments, results show that 
as the Au400
4+ ion energy increases the ratio of molecular to fragment ion also increases in 
a non-linear fashion. That is, the SI yield of [M]- increases more than the SI yield of the 
low mass fragments. For the higher mass fragments (m/z 509 and 511), the opposite trend 
is observed where the ratio of [M]- to larger fragment ions decreases. In positive mode 
TOF-SIMS, the molecular ion emission also increases with the Au400
+4 projectile energies. 
Closer inspection shows that as the Au400
4+ ion energy increases a proportional increase in 
M+, [M+Na]+ and [2M+Na]+ emission is observed (Figure 5.4c and Appendix 12). These 
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positive and negative mode TOF-SIMS results suggest that as the Au400
+4 ion energy 
increases the nanoparticle penetration into the sample also increases thus creating a larger 
emission volume in a way that scales the emission of intact molecular and fragment ions. 
In a different scenario, an increase of the 20 keV Arn
+ cluster size from 500 to 2000 
atoms (or decrease in the Eatom) results in an increase in SI yield of M
-, head group 
fragments and fatty acid fragments (Figure 5.4b). The SI yield of the molecular ion is rising 
at a faster rate than all of the fragment ions as the cluster size ranges from 500 to 2000 
argon atoms, being the most significant between Ar1500 and Ar2000 (Figure 5.4b, Appendix 
11 and Appendix 8b). This SI yield dependence on the Arn
+ cluster size is in good 
agreement with recent observations by Yokoyama et al. using 20 keV Arn=2000-5000 cluster 
impacts.54 Previous report of Arn cluster impacts at 10-40 eV/atom have also shown that 
larger fragments are more favorable with the Arn projectile size increase.
18 These results 
suggest that as the size of the Arn
+ projectile increases a larger impact cross section is 
achieved that enhances the emission volume; the weak forces that hold the Arn cluster 
together do not lead to penetration/implantation into the surface. Notice that this 
mechanism is very different from that of the nanoparticle Au400
+4 projectiles. 
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Figure 5.4. Secondary ion yields as a function of the nanoparticle Au400
+4 projectile energy 
or Arn
+ cluster size for a lipid model target of phosphatidylglycerol (18:0-18:1 PG) a) 
Au400
+
 and b) Arn
+ negative and c) Au400
+
 positive mode. Notice the break in vertical axis 
in b).  
 
 
 109 
5.4.4 SI Yield as a Function of Chemical Environment 
SIMS is a very useful mass spectrometry tool for the analysis of biological matrices 
as previously described.2, 16, 18, 32, 43, 55-56 The chemical environment (matrix) of compounds 
of interest has a significant impact on the limit of detection, ionization efficiency and ion 
suppression for TOF-SIMS and for other ionization sources.57 To evaluate the influence a 
matrix has on the SI yield, we compared the emission from the single lipid component 
sample to the emission from a sample containing a mixture of all five-lipid classes at equal 
concentrations. The protonated and deprotonated molecular ion of each lipid was utilized 
for comparison in positive and negative mode TOF-SIMS, respectively. The analysis of 
the sulfatides mixture in negative and positive mode TOF-SIMS using Ar1000
+
 showed no 
suppression or enhancement for the deprotonated/protonated molecular ion (Figure 5.5a 
and Figure 5.5b). For Bi3
+ analysis, in negative mode TOF-SIMS ion enhancement is 
observed for the sulfatides and in positive TOF-SIMS no change is observed from the 
single standard to the mixture (Figure 5.5d and Figure 5.5c). Typically, sulfatides are 
preferentially ionized in negative ionization mode and this could contribute to the fact that 
opposite trends are observed between the two ionization modes for Bi3 analysis. For a 
characteristic ion of the sulfatide lipid class (HSO4
-) the SI yields of the fragments are on 
the same order of magnitude in both alone and as a mixture using Ar1000
+ and Bi3
+projectiles 
(data not shown). For the sphingomyelin class of lipids, positive mode TOF-SIMS shows 
no suppression in the SI yield of the [M+H]+, however in negative mode TOF-SIMS, an 
order of magnitude decrease is observed between the SI yield of the single lipid and the SI 
yield of the lipid mixture (Figure 5.5a and Figure 5.5b). Using the Bi3
+ projectiles, no 
significant changes are observed between single lipid and lipid mixture analysis of 
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sphingomyelin in positive ionization mode TOF-SIMS and a slight decrease in SI yield is 
observed in negative mode TOF-SIMS (Figure 5.5c and Figure 5.5d). 
 
Figure 5.5. Secondary ion yields of intact molecular ions from a single lipid standard 
sample and a mixture of lipid standards sample in a) positive mode Ar1000
+, b) negative 
mode Ar1000
+ c) positive mode Bi3
+ d) negative mode Bi3
+.  
 
Analysis of phosphatidylglycerol in positive mode TOF-SIMS demonstrates no 
significant changes with the Ar1000
+ projectiles and a small decrease in SI yield using the 
Bi3
+ projectiles (Figure 5.5a and Figure 5.5c). For the analysis of phosphatidylglycerol in 
negative mode TOF-SIMS, no ionization suppression or enhancement is observed for 
either of the primary ion projectiles (Figure 5.5b and Figure 5.5d). SI yields of 
characteristic fragment peaks for phosphatidylglycerol (i.e., m/z 153 and 171) also showed 
no change between single and mixture conditions (data not shown). As previously 
 111 
mentioned, phosphatidylcholine is a lipid typically analyzed in positive mode TOF-SIMS; 
in positive mode TOF-SIMS, the SI yield of the [M+H]+ ion does not show a major matrix 
effect and no large changes in ion abundance are observed for Ar1000
+ or Bi3
+ (Figure 5.5a 
and Figure 5.5c). In negative mode TOF-SIMS, a different trend is seen for 
phosphatidylcholine, with suppression in the mixture signal observed using Ar1000
+ and an 
enhancement in SI yield observed for Bi3
+ projectiles (Figure 5.5b and Figure 5.5d); this 
difference in trend between positive and negative mode TOF-SIMS could be attributed to 
the fact that phosphatidylcholine is preferentially ionized in positive mode TOF-SIMS. A 
previous study by Jones et. al. of matrix effects in TOF-SIMS used phosphatidylcholine as 
a complex matrix while looking for targeted drug analytes.57 It was determined that the 
lipid had a very strong suppression effect on the abundance of the molecular ion of the drug 
due to its proton affinity.57 In our study we observed a similar suppression effect on the 
pseudo-molecular ions of the lipids in the mixture, potentially from the presence of 
phosphatidylcholine (Figure 5.5a and Figure 5.5b). For the analysis of 
phosphatidylethanolamine by Ar1000
+ there is less than 10-fold suppression of ion signal 
going from the single lipid to the mixture of lipids (Figure 5.5a and Figure 5.5b). No major 
changes are observed using Bi3
+ for the [M-H]-  or [M+H]+ from phosphatidylethanolamine 
(Figure 5.5c and Figure 5.5d). No major changes in SI yield are seen for the characteristic 
peaks (m/z 141 and 196) of the phosphatidylethanolamine lipid class. In general, these 
matrix studies have shown that matrix effects are minimal on the SI yield of lipid standards 
when the lipid is analyzed in either ionization polarity. According to previous studies, 
chemical environment of a sample has a large impact on the SI yield of targeted molecules 
as shown with the large suppressive effects phosphatidylcholine has on the M and the 
 112 
enhancement effects cholesterol induced when used as a comparative matrix.57-58 More 
recently, matrix enhanced TOF-SIMS has been developed in order to more easily and 
efficiently ionize samples within complex biological matrices via TOF-SIMS. 57, 59-61 Our 
studies suggest that whether compounds of interest exist as a single standard or co-exist as 
a mixture of lipids does not significantly change the secondary ion yield of the molecular 
ion of the selected lipids regardless of primary ion identity or ionization mode. 
5.5 Summary and Conclusions 
In this paper, we provide detailed information on the TOF-SIMS fragmentation pattern 
for sphingomyelins, phosphatidylcholine, phosphatidylglycerol, sulfatides and 
phosphatidylethanolamine lipid classes. Typical mass spectra for common lipids are shown 
and discussed based on their fragmentation patterns. Changes in secondary ion yields were 
analyzed as a function of the primary ion (Bi3
+
 vs Ar1000
+
 and Au3
+ vs Au400
+4) using TOF-
SIMS. For the case of lipid analysis, the results suggest that for polyatomic projectiles (Bi3
+
 
and Au3
+), the increase in the primary ion energy leads to an increase in the SI yield. 
However, larger SI yields are obtained for molecular ions using nanoparticle projectiles. 
Two different trends were observed in the case of the nanoparticle projectiles (Arn
+
 and 
Au400
+4) that may be related to their intramolecular forces. For example, in the case of 
Au400
+4 projectiles, as the projectile energy increases a larger SI yield is observed for 
fragment and molecular ions, with small variation on their relative ratio. That is, the larger 
the Eatom for Au400
+4 projectiles the larger the SI yield. In the case of the Arn
+ projectiles, 
the lower the Eatom the larger the SI yield. We interpret these effects as consequence of two 
ways to increase the desorption volume: i) the larger the incident energy in the case of the 
Au400
+4 projectiles the larger the penetration depth and emission volume, and ii) the higher 
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the number of atoms in the Arn
+ projectiles the larger the impact cross section and emission 
volume. The matrix studies showed that the sample composition has a minimal effect on 
the desorption yields of intact molecular ions of familiar lipids and no correlation with the 
type of primary ion was observed. This work further provides more information on the 
main factors that affect the SI yield as well as characteristic patterns that allow lipid 
analysis in biological environments using TOF-SIMS. 
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6.1 Abstract 
The diverse and complex nature of the lipidome makes identification and quantitation of 
lipids a challenging task. Combinations of analytical techniques has been deemed 
necessary to reveal a comprehensive lipid profile from biological samples. In this chapter, 
a new workflow based on liquid chromatography, trapped ion mobility spectrometry 
(TIMS), and high-resolution mass spectrometry was developed and evaluated for the 
analysis of a variety of lipid classes and for the discovery and quantitation of lipids in 
Dictyostelium discoideum as a function of the biological cycle.  The TIMS analyzer 
permitted the separation of lipid classes as well the separation of sn isobars (average R of 
140). Typical limits of detection are reported below 10 pg/μl for over 10 different lipid 
classes using tandem liquid chromatography, mobility and mass separations. The proposed 
workflow permits untargeted and targeted analysis with higher confidence and high 
sensitivity. 
6.2 Introduction 
Lipidomics is an up-and-coming area of study due to the important role lipids play 
in various biological systems and environments.1-2 Lipids are fats, and are involved in cell 
signaling, energy storage, membrane make-up, and play major roles in the regulation and 
function of cellular processes. Deviations in typical lipid levels or disruptions in lipid 
metabolism have been linked to diseases such as Alzheimer’s Disease, Parkinson’s Disease 
and Neuronal Ceroid Lipofuscinoses (NCLs).1, 3-5 Traditional lipidomic analyses include 
the use of liquid chromatography coupled to tandem mass spectrometry (LC-MS) for the 
separation and identification of the compounds within complex biological matrices.6-11 
Numerous methods of lipid extraction, chromatographic separation and mass spectrometric 
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separation and detection have been recently developed; the specific approach depending 
on the analytical or biological challenge at hand. Lipid quantitation includes the use of 
tandem mass spectrometry (MS/MS), specifically multiple reaction monitoring (MRM) for 
targeted identification and quantification based on transitions between the molecular ion 
and characteristic fragment ions.11 Recent analytical lipidomic developments stray away 
from targeted approaches, which tend to limit the extent to which a biological profile can 
be identified. Non-targeted analyses may provide less accurate identifications; however, 
using an  non-targeted approach allows for a comprehensive lipid profile which can also 
be re-processed and analyzed should the biological question change, or,  as developments 
in lipid research are accomplished.12 
In addition to the widely used LC separations, ion mobility is becoming a common 
technique for separations and identifications of lipids within biological samples.13-22 IMS 
allows separation of all lipid classes in a single analysis in significantly less time than a 
traditional LC approach. Differentiation of lipid isomers has been achieved using various 
ion mobility spectrometers such as high field asymmetric ion mobility spectrometry 
(FAIMS) and drift tube ion mobility spectrometry (DT-IMS).15-17, 21-23 For example, 
FAIMS has been utilized by several research groups for the separation of three types of 
lipid isomers including: sn-, double bond and cis/trans positional isomers.15-16, 21 Baseline 
or near-baseline separations of lipid isomers are achieved with FAIMS following 
modifications such as changing bath gas composition (i.e. increasing %He),15, 21 the use of 
adducts (i.e. silver-ion adducts),16, 22 or upon addition of chemical modifiers (e.g., butanol 
and propanol).22 High resolution DT-IMS has been used for separations of double bond 
positional isomers, geometrical isomers and sn–positional isomers.17, 23 The coupling of 
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liquid chromatography to IMS-MS is becoming a more popular and standard method for 
lipidomic analyses of biological samples 13, 17, 24-28 
In this research, the lipids in Dictyostelium discoideum (D. discoideum) cells are 
identified at different points of the cell cycle. D. discoideum are cells that, like most 
organisms, adapt to their environment to best protect themselves from harm or death; they 
can emit chemotactic responses to signals generated by cyclic adenosine 3’, 5’-
monophosphate (cAMP) when subjected to adverse conditions.29-32 The processes of 
growth and development in D. discoideum are two independent routes, and only one can 
occur at a time.32 In order for the development stage to occur and the cells to migrate into 
a multicellular body, they must be depleted of nutrients. If nutrients are reintroduced during 
the earlier stages of development, the process will be reversed and the cells return to the 
growing phase.32 There are different stages of the aggregation process, ranging from 
migration to culmination, which results in a full fruiting body.33 The development of the 
full fruiting D. discoideum occurs after approximately 24 hours of continuous starvation.33 
D. discoideum are considered “model organisms for biomedical research” by the National 
Institute of Health, because of their ability to exchange between single and multicellular 
organisms in their biological cycle and the conservation of various cell processes such as 
cell-to-cell interactions and signaling from these amoeba to eukaryotic cells.32, 34-40 It is 
interesting to study how certain cell components (i.e. lipids and proteins) are altered during 
the cell’s life cycle to assist in the understanding of mechanisms of chemotaxis and the 
impact the movement has on the cell structure and make-up.  
In this research, a new workflow based on liquid chromatography, trapped ion 
mobility and high-resolution mass spectrometry is used for the separation and identification 
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of lipids in D. discoideum cells. The capabilities of LC-TIMS.MS/MS are evaluated for a 
series of lipid classes and sn-positional isomers. In addition to confirming the lipids of 
interest using RT, accurate mass and fragmentation pattern, the proposed workflow also 
provides accurate CCS. This work indicates the importance of multidimensional 
separations in lipidomic analysis, showcasing the analytical capabilities of trapped ion 
mobility when coupled to both mass spectrometry and liquid chromatography. 
6.3 Experimental Parameters 
6.3.1 Standards and Chemicals 
All solvents were purchased from Fisher Scientific (Pittsburg, PA) and were of LC-MS 
quality or better. Pooled human plasma was purchased from Innovative Research (Novi, 
MI, USA). Lipid standards of sulfatides [131305, Brain, Porcine, (major component 
18:1/24:1 ST)], sphingomyelin [860061, Egg, Chicken (major component 18:1/16:0 SM)], 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine [850355, (16:0 PC DPPC)], 1-stearoyl-2-
palmitoyl-sn-glycero-3-phosphocholine [850465, (18:0-16:0 PC)], 1-palmitoyl-2-stearoyl-
sn-glycero-3-phosphocholine [850456, (16:0-18:0 PC)], 1-stearoyl-2-myristoyl-sn-
glycero-3-phosphocholine [850464, (18:0-14:0 PC)], 1-myristoyl-2-stearoyl-sn-glycero-3-
phosphocholine [850446, (14:0-18:0 PC)], 1-palmitoyl-2-myristoyl-sn-glycero-3-
phosphocholine [850454, (16:0-14:0 PC)], 1-myristoyl-2-palmitoyl-sn-glycero-3-
phosphocholine [850445, (14:0-16:0 PC)], 1-stearoyl-2-oleoyl-sn-glycero-3-phospho-(1'-
rac-glycerol) (sodium salt) [840503, (18:0-18:1 PG)] and 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine [850745, (14:0 PE)] and the SPLASH Lipidomix [330707] were 
purchased from Avanti Lipids Inc. (Alabaster, AL) and used as received. Calibration curves 
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were created and analyzed with the analytes and the SPLASH mixture was used as the 
deuterated internal standard for several lipid classes.  
6.3.2 Calibration Standard Preparation. 
 Lipid standard calibration curves were created at six levels ~1700 ppb to 0.05 ppb 
depending on the lipid class. For determination of LODs, a stock solution of lipid analyte 
mixture was prepared at ~100 ppm and diluted in IPA:ACN for the use in each calibration 
point. An aliquot of SPLASH Lipidomix was also diluted in 1:1 IPA:ACN and 
subsequently used in a dilution series to calculate LOD for each standard in the mixture. A 
secondary calibration curve was developed following LOD calculation which contains a 
set deuterated standard concentration with a variation in the analyte concentration. The 
concentration of the SPLASH Lipidomix internal standard ranged from 13-2330 ng/mL 
depending on the lipid class and its initial concentration in the commercial mix.  
6.3.3 Dictyostelium discoideum Cell Preparation. 
Wild type Ax2 D. discoideum cells were grown at room temperature in Formedium 
HL-5 shaking culture as previously described 41-42. Briefly, mid-log phase cells at 2x106 
cells/mL were collected by centrifugation at 1,500xg for 5 minutes and resuspended in 
deionized water. The cells were again collected by centrifugation, washed twice by 
resuspension and centrifugation and collected in the same manner. The cell pellets were 
frozen in a dry ice ethanol bath and stored at -800C. For developing cells, the mid-log phase 
cells were collected by centrifugation at 1,500 x g for 3 minutes and washed twice by 
resuspension in PBM (20 mM KH2PO4, 10 μM CaCl2, 1 mM MgCl2, pH 6.1); collection 
of the cells was performed by centrifugation. After various starvation times (0 hours, 6 
hours and 18 hours) cells were resuspended in PBM to 5x106 cells/mL, developed in 
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shaking culture, collected, and washed three times with deionized water. Pellets were 
frozen as described above and stored at -800C.  
6.3.4 Lipid Extraction 
Lipid extraction from pooled human plasma and D. discoideum cells was based on 
a single phase, chloroform-free lipid extraction from plasma.43-45 Briefly, pooled human 
plasma or D. discoideum cell pellets were removed from the freezer and allowed to thaw 
over ice. Following thawing, 30 uL of plasma or a cell pellet were spiked with SPLASH 
mixture, ammonium formate (for a final concentration of 10 mM) and butylhydroxytoluene 
(BHT) as an antioxidant (final concentration of 10 μM) and 100 uL of 1:1 
butanol:methanol. The samples were disrupted using a mechanical pestle for ten seconds, 
and an additional 200 uL of butanol:methanol was used to rinse the pestle into the 
Eppendorf containing the matrix. The lipids were vortexed for 20 seconds and sonicated 
for 30 minutes at 20º C. Following sonication, the plasma or cells were centrifuged for 20 
minutes at 16000 x g at 20º C and the supernatant (~300 μL) transferred to an autosampler 
vial with an insert.  
6.3.5 LC-TIMS-MS/MS Separation 
After extraction, the lipids were separated by an Acclaim 120 chromatography 
column (2.1 x 250 mm; 5 μm; 120Å; C18) during a 20-minute multistep gradient using a 
Shimadzu Prominence HPLC system consisting of two 20AD pumps, a SIL-20AC auto-
sampler and a CTO 20-A column oven held at 55 °C flow rate of 0.75 mL min-1 (Kyoto, 
Japan). Separation parameters were modified from methods reported by Della Corte et al.46 
and Hu et al.47 following a 20 μL injection, mobile phase B was held at 25% for 0.2 minutes 
where it was increased to 50% B at 1.5 minutes. Over 3.5 minutes, mobile phase B 
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increased to 85% and then to 100% between 5 and 10 minutes. Mobile phase B was held 
at 100% from 10 and 15 minutes and decreased back to 25% at 16 minutes. The column 
was held at 25% B for four minutes for re-equilibration. Mobile phase A consists of 40% 
acetonitrile in water, 10 mM NH4COOH and B is 10% acetonitrile and 1% water in 
isopropyl alcohol with 10mM NH4COOH. The mobile phases were constant between 
positive and negative ionization modes. The HPLC was coupled directly to a commercial 
timsTOF (Bruker Daltonics Inc., Billerica, MA). Samples were ionized using an 
ionBooster ESI source in both negative and positive ionization mode. Typical ionBooster 
operating conditions were 1750 V capillary voltage, 400 V end plate offset, 400 V charging 
voltage, 1.5 bar nebulizer pressure, 3.0 L/min dry gas, 250 °C dry heater and 200 °C 
vaporizer.  
For wide range mobility analysis and CCS calculation of PC isomers, a custom-
built TIMS-TOF MS based on the maXis impact Q-ToF MS (Bruker Daltonics Inc, 
Billerica, MA) was utilized. The gas velocity was defined by the entrance and exit TIMS 
roughing impedance (P1 = 2.6 and P2 = 1.0 mbar) and a voltage and time ramp of 280 V 
and 100 ms with Vout = 60 V were used. For narrow mobility selection experiments (higher 
resolving power), the velocity of the gas was increased (P1= 3.2 and P2=1.0 mbar) and a 
ramp of 30 V  with a 1000 ms ramp time was utilized. A Vpp = 270 V and 880 kHz 
radiofrequency was kept constant for all the experiments and allowed for radial 
confinement of the ions within the TIMS analyzer. For LC-TIMS-MS/MS analysis, a 
Commercial TIMS-tof parameters were optimized to detect lipids in the mobility range 
between 0.70 and 1.70 Vs/cm2 with an accumulation time of 100 ms and a ramp time of 
350 ms using a dual stage trapped TIMS analyzer. 
 129 
MS2 parameters were optimized as follows: TIMS ramp time of 150 ms from 0.5-
1.80 V S/cm2, the duty cycle was locked to 100% during acquisition. For PASEF, 8 MS/MS 
scans were collected during a 1.40 sec cycle time, precursor ions were set for 1 repetition 
with a cycle overlap of 4. A target intensity of 300000 cts/s was used with active exclusion 
on, a release time of 0.4 min and reconsideration was activated if current intensity was 
measured 4x higher than previous intensity. A collision energy of 42 eV was set for m/z 
622, 922, and 1521, each with a charge state of 1 and a width of 2.00. Auto-MS/MS 
parameters were optimized as follows: 20 precursors, an absolute threshold of 5000, a 20x 
smart exclusion and active exclusion after 2 spectra with reconsideration if a 5x intensity 
increase is observed. Ions below m/z 350 were excluded from MS/MS fragmentation. CID 
parameters were set for singly charged species as follows: m/z 622, 922 and 1521 with a 
width of 2.00 and collision energy of 38.5 eV. MS/MS for bbCID parameters were set at 
10 eV collision energy in MS and 38.5 eV for MS/MS. 
 
6.3.6 Data Processing and Analysis 
LC-TIMS-TOF MS data were processed using Data Analysis software v. 5.0 
(Bruker Daltonics Inc, Billerica, MA). The lipids from the D. discoideum cells and human 
plasma were identified from the LC-PASEF-MS acquisition. The “Find PASEF” feature 
in Data Analysis was used to obtain an initial list of precursor and fragment ions which 
was searched for familiar, head group, fatty acid and fragment ions from lipids.  SimLipid 
6.02 (Palo Alto, CA) was used for confirmation of the initial identifications based on 
accurate mass and fragmentation pattern. Scans with MS/MS were selected for 
consideration in the identification parameters. For lipid identification using SimLipid, the 
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following parameters were used: a precursor mass tolerance of 0.12 Da was implemented 
with fragment mass errors of 2.5 ppm. All lipid classes, categories and subclasses were 
selected for potential matching. In negative mode the [M-H]- adduct was searched and in 
positive mode, [M+H]+, [M+Na]+, [M+K]+, and [M+NH4]
+ were utilized for 
identifications. For incorporation into the lipid identification table, the lipid identification 
had to occur for each strain of cells at in at least two scans of a single data file and in at 
least two of the three replicates analyzed.  
6.4 Results and Discussion 
TIMS-MS experiments were performed on pairs of sn-positional isomers of PC 
lipids for CCS calculation, evaluation of variability and reproducibility of TIMS CCS 
measurements and high-resolution separation of isomeric lipids. Pairs of isomeric lipids 
include PC (14:0/16:0) and PC (16:0/14:0) at m/z 706.5381 for [M+H]+, 728.5201 for 
[M+Na]+, and 744.4940 for [M+K]+; PC (14:0/18:0) and PC (18:0/14:0) at m/z 734.5694 
for [M+H]+, 756.5514 for [M+Na]+, and 772.5253 for [M+K]+; and PC (18:0/16:0) and PC 
(16:0/18:0) at m/z 762.6007 for [M+H]+, 784.5827 for [M+Na]+, and 800.5566 for [M+K]+. 
Collisional cross sections of the individual lipids were calculated on five different days to 
determine the interday reproducibility and variability of the TIMS CCS calculations. In 
TIMS, CCS calculations are possible using internal or external calibration using 
compounds of known mobility (i.e., Tuning Mix). The CCS for the individual compounds 
of the sn-positional isomers are reported in Table 6.1. Utilizing low resolution ion mobility 
analysis, and based on the reported CCS with their errors over the five days, separation 
between the sn isomeric compounds is not observed. Figure 6.1 depicts single band CCS 
profiles for each PC lipid over the 5-day analysis. Note the minimal shift in peak apex for 
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each analysis. The relative standard deviations in the calculated CCS for each day of 
analysis remains <0.25%. These minimal changes can attest to the stability and 
reproducibility of the TIMS platform of ion mobility spectrometry. 
Upon adjusting the TIMS parameters to achieve high resolution analyses (increased 
pressure difference, 30 V TIMS ramp and 1000 ms ramp times, Sr = 0.3 V/ms) baseline 
separation is achieved between PC(14:0/16:0) and PC(16:0/14:0) (shown in purple and 
yellow), PC(14:0/18:0) and PC (18:0/14:0) (shown in green and red) and PC (16:0/18:0) 
and PC (18:0/16:0) (shown in blue and orange) (Figure 6.2). Under these conditions, 
typical resolving powers of R~ 130-150 were observed, and a resolution between the 
[M+H]+ and [M+Na]+  bands of each PC lipid r~ 1.1 - 1.5. Previous works have shown 
partial separation of sn-lipid isomers using FAIMS 15, 22 and DT-IMS 17, 23; however, unlike 
in TIMS analysis, bath gas modifiers or unusual ion adducts (e.g., Ag16, 22-23) were 
necessary. Baseline separations of sn-positional isomers using silver ion adducts have been 
shown using DT-IMS at lower resolving power and can be probably be reproduced with 
TIMS.23 Moreover, based on the higher resolving power of TIMS compared to DT-IMS, 
we can postulate that PC isomers with variation of the double bond position are likely 
separated by TIMS, since these separations have been shown using DT-IMS at lower 
resolving powers. 23   
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Table 6.1: sn-positional isomer CCS and %RSD over 5 days 
Interday 
Reproducibility (n=5) 
K0 (cm
2V-1s-1) CCS (Å2) % RSD K0 (cm2V-1s-1) CCS (Å2) 
[M+H]+ [M+Na]+ 
PC 18:0-16:0 0.6971 ± 0.0013 292.921 ± 0.543 0.23 0.6825 ± 0.0010 297.803 ± 0.449 
PC 16:0-18:0 0.6985 ± 0.0021 292.326 ± 0.868 0.13 0.6839 ± 0.0001 297.706 ± 1.386 
PC 16:0-14:0 0.7311 ± 0.0022 279.697 ± 0.855 0.09 0.7162 ± 0.0023 285.340 ± 0.900 
PC 14:0-16:0 0.7316 ± 0.0019 279.472 ± 0.710 0.08 0.7163 ± 0.0026 285.295 ± 1.042 
PC 18:0-14:0 0.7144 ± 0.0023 285.997 ± 0.914 0.12 0.7012 ± 0.0026 291.239 ± 1.060 
PC 14:0-18:0 0.7151 ± 0.0025 285.740 ± 1.013 0.13 0.7015 ± 0.0031 291.084 ± 1.291 
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Figure 6.1: Interday analysis of PC lipids (n=5) 
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Figure 6.2: Ion mobility profiles for sn-isomeric phosphatidylcholine lipids using high 
resolution TIMS-MS. Note the shift in CCS between [M+H]+ and [M+Na]+ adducts 
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A significant difference between TIMS and other IMS variants is the possibility to 
decouple the mobility separation from the analysis time, which allows for variable 
sensitivity depending on the chosen duty cycle. In a one stage TIMS, a mix of lipids was 
analyzed via LC-TIMS-MS with varying duty cycle (10-50%). That is, a 100 ms TIMS 
separation was considered with duty cycles ranging from 10-50%. Notice that this has a 
direct impact on the number of points recorded in the LC domain (Figure 6.3). As the duty 
cycle increases (i.e., fill time increases), the signal response increases at the cost of 
decreased sampling points in the LC domain. Although an increase in signal response is 
typically a desirable effect, the increase in LC step may be a deterrent in cases where RT 
is used as an identifier for the compound of interest or highly resolved chromatographic 
peaks are necessary.  
  
Figure 6.3: Signal changes in response to changes in duty cycle of the TIMS-MS 
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The addition of IMS to traditional LC-MS workflows can lead to a loss in 
sensitivity. However, due to the trapping nature of TIMS, no change, or an increase in the 
detection sensitivity is expected. To further evaluate the analytical potential of LC-TIMS-
MS, limits of detection (LODs) were calculated for lipid classes and subclasses using 
deuterated and non-deuterated standards. Tables 6.2 and 6.3 provide LODs and limit of 
quantitation (LOQs, three times LOD) results in the chromatographic and ion mobility 
domain for the analytes in negative (Table 6.2) and positive (Table 6.3) mode, depending 
on the preferential ionization polarity of the lipid. The extracted ion 
chromatogram/mobilogram for each m/z was integrated and used to the calculate the LOD. 
Reported LODs for both positive and negative mode using LC-MS are typically reported 
under 1 pg/μL (Tables 6.2 and 6.3), exceptions include PA 12:0/12:0 in negative ionization 
mode and PC 15:0/18:1 d7, TG (15:0/18:1 d7/15:0) and PC 16:0/16:0 in positive ionization 
mode. Good linearity is reported for all analytes throughout the curve R2>0.98. For LOD 
calculation using LC-TIMS-MS, LODs are typically equal to or higher than those reported 
from LC-MS. A linear trend can be observed when a comparison is made between the LOD 
of each analyte calculated from analysis with and without TIMS separation (Figure 6.4). 
The LODs and LOQs are on the same order of magnitude between LC-MS and LC-TIMS-
MS and minimal losses in sensitivity are observed with the addition of the TIMS domain. 
With the TIMS dimension included in the analysis, LODs are below 1 pg/uL except for PG 
15:0/18:1 d7, PE 18:1/16:0, PG 18:0/18:1, PA 12:0/12:0 and PE 14:0/14:0 in negative 
mode and PC 15:0/18:1 d7, TG 15:0/18:1 d7/15:0), and PE 14:0/14:0 in positive ionization 
mode. Good linearity is observed for the analytes across the calibration concentrations 
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using LC-TIMS-MS. These results are comparable to previously reported lipid LODs using 
LC-IMS-MS approaches.28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: LOD comparison between LC-TIMS MS and LC-MS for neat lipid standards 
(top). Reproducibility and accuracy parameters for lipid standards spiked in blood plasma 
at two different spiked levels (1x and 20x) with respect to a control mix  
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Table 6.2: Limits of detection using timsTOF with and without TIMS for lipids preferentially ionized in negative mode            
Note: *= visually estimated LOD 
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Table 6.3: Limits of detection using timsTOF with and without TIMS for lipids preferentially ionized in positive mode  
+ [M+Na]+, + + [M-H2O+H]
+, +++[M+NH4]
+, *=visually estimated 
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The lipid profile of the D. discoideum cells was obtained from LC-TIMS-MS/MS 
data using the SimLipid software to obtain a high throughput lipid identification output. 
Appendix 13 includes the lipids identified from the WT D. discoideum cells using 
SimLipid and includes the m/z, retention time, lipid identity and the fragments that lead to 
its identification. Additionally, presence/absence of the lipid in the three growing 
conditions is noted. Total lipid profiling from D. discoideum cells has not been reported; 
however, several studies have been performed that identify lipid subclass profiles from the 
cells. Fatty acid profiles for the cells have been reported with relative abundances of the 
fatty acids based on their chain length and degrees of unsaturation.48-51 Although our lipid 
identifications do not specifically extract fatty acid chains, observation of the fatty acid 
chain fragments observed in negative mode allows for comparison of our cells to those 
reported by Blacklock et al.48 The most abundant fatty acids in the D. disocoideum cells 
were reported to be 18:2 and 18:1 chains at ~36% and ~32% of the total lipids.48 A majority 
of the lipids we identify contain one or both of the 18:2 or 18:1 fatty acid chains, which 
can be identified based on their [RCOO]- ion at m/z  of 281.248 and 279.232, respectively 
(Appendix 13). The other most abundant fatty acids reported for D. discoideum cells 
include 16:0, 16:1 and 16:2, which are also incorporated in several of the identified lipids 
we report in Appendix 13. 48 
Previous reports of intact lipids in D. discoideum focus on sphingolipids as a class 
of lipids.38 A series PI-Cer (t36:0(2OH)) (m/z: 840, C42H83NO13P), PI-Cer (t38:0(2OH)) 
(m/z: 868, C44H87NO13P) and PI-Cer (t40:0(2OH)) (m/z: 896, C46H91NO13P) has been 
observed in D. discoideum cells  and has been previously reported by Birch.38 The 
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SimLipid identification parameters were not able to ID this series of lipids, and the 
identifications were manually performed through analysis of the MS2 spectrum for each 
intact lipid. Identifying fragments for the PI class of lipid include head groups at m/z 259 
and 241 and the fatty acid chain fragments. The lipid PI-Cer (t34:0(2OH)) at m/z 812 
(C40H79NO13P) also belongs to this series of sphingolipids but has not been reported 
previously. A sphingolipid was also reported at m/z 700.5658 (C40H79NO6P); however, we 
identify this lipid as PE (P-16:0/18:1) based on the typical PE head group fragment at m/z 
140 and a fragment at 281 corresponding to the 18:1 fatty acid chain.38  
A variety of other glycerophospholipds have been identified through our analyses, 
including lipids within the PE, PG and PS subclasses (Appendix 13). Although a 
comprehensive lipid profile has not been identified for D. discoideum, reports have been 
published regarding general lipid classes observed in the cells. These reports have shown 
that PE and PC are both represented in the lipidomic profile of D. discoideum as well as 
PG and PS in lower abundances.52-53 Based on initial observations of presence/absence of 
the lipids during the various times of starvation, most of the identified lipids are present at 
the vegetative state and 18 hours after starvation; however, many are missing during the 6 
hours of starvation time point (Appendix 13). Coe and Long have shown the decrease in 
lipid composition during the early stages of aggregation followed by an increase in the total 
lipids during the culmination stage after 24 hours.54 
A distribution of lipid class, m/z and CCS of the lipids identified from the D. 
discoideum cells is displayed in Figure 6.5. The trends are consistent with previously 
reported trends. Typically, as the mass-to-charge of an ion increases, its size or CCS also 
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increases.18-19 Notice that in our approach, the trends are also “build as you go” using the 
identification workflow.  
 
 
 
 
 
 
 
 
 
Figure 6.5: Lipids from D. discoideum cells depicted by subclass, m/z, CCS, and RT 
 
The use of internal standards allows for further evaluation of lipid changes. With the 
addition of deuterated lipids as internal standards (Avanti’s SPLASH Lipidomix), the 
ability to obtain quantitative lipidomic results is achieved. The quantitation of lipids allows 
us to report discrete concentration values of various lipid class, and subclasses detected 
within the D. discoideum cells rather than merely provide qualitative data such as 
presence/absence or relative abundances. Changes in specific lipid abundances between 
the vegetative, 6 and 18 hours of starvation are observed and reported (Figure 6.6).  For 
two subclasses of phosphoglycerolipids, phosphatidylglycerols and 
phosphatidylethanolamines, a pattern is observed for the changes in the identified lipids 
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over D. discoideum starvation. As the cells are starved, an increase in lipids is observed 
with 18 hours following starvation typically having the highest abundance of lipids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Quantitation results of select lipid subclasses PGs and PEs 
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6.5 Conclusions 
In this work, TIMS-TOF MS and LC-TIMS-TOF-MS were used for various analyses of 
lipids, including separations of sn-isomeric phosphatidylcholines, limits of detection and 
dynamic range calculations for several lipid classes and identification and quantitation of 
lipid profiles from extracts of Dictyostelium discoideum cells. Calculated limits of 
detection show good association between the chromatographic domain and ion mobility 
domain and are lower than those previously reported with similar analytical methods. 
Separations of sn-positional isomers was achieved without the need for modifications in 
the separation technique or ionization. Comparison between lipid profiles of D. discoideum 
cells shows differences during the growth and development of the cells The addition of 
TIMS to traditional LC-MS/MS lipidomic analyses provides additional points of 
identification for lipids (CCS) and allows for differentiation of isomeric species, which 
may not be possible with LC alone.  
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APPENDICES 
Appendix 1: Theoretically calculated structures and their corresponding coordinates for the 
9 OH-PCBs analyzed  
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3-OH-PCB 180  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OH-PCB 180 
Atomic Number      X                 Y                   Z  
 1          6       0.000000    0.567147    0.000000 
  2          6       1.129686    1.408718    0.000000 
  3          6      -1.235544    1.297961    0.000000 
  4          6       1.105091    2.786678    0.000000 
  5          6      -1.266394    2.709902    0.000000 
  6          6      -0.098837    3.477817    0.000000 
  7          6       1.637825   -3.077763    0.000000 
  8          6       0.391057   -3.816564    0.000000 
  9          6       1.466002   -1.619990    0.000000 
 10          6      -0.818599   -3.162604    0.000000 
 11          6       0.218987   -0.934478    0.000000 
 12          6      -0.914951   -1.779565    0.000000 
 13          8       2.743743   -3.636466    0.000000 
 14         17      0.513881   -5.560582    0.000000 
 15         17     -2.349436   -4.063282    0.000000 
 16         17      3.097831   -0.899066    0.000000 
 17         17     -2.845436    0.579742    0.000000 
 18         17     -2.790401    3.576302    0.000000 
 19         17     -0.138497    5.220604    0.000000 
 20         17      2.639540    3.639031    0.000000 
 21          1       2.099537    0.952534    0.000000 
 22          1      -1.902603   -1.381077    0.000000 
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Appendix 2: Typical response curves for LC-TOF MS as a function of PCB concentration 
in human blood plasma. Note the high signal from the 0 ppt sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 3: Scheme of TIMS cell 
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Appendix 4: Matrix factor across urine samples from ten donors spiked at 400 and 75 
ng/mL 
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Appendix 5: Candidate structures from theoretical calculations of opioids and metabolites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Naloxone 
Atomic           
No.        X                 Y                   Z 
 12  -0.389246    0.691294    0.661080  
 12  -1.193475   -0.609391    0.242226  
 12   0.742784    0.701494   -0.375141  
 12  -1.232260    1.932523    0.589084  
 12   0.380309    0.578308    2.091895  
 12  -2.583029   -0.508536    0.530478  
 12  -0.657303   -1.719962   -0.505908 
 12   1.351691   -0.675228    0.057094  
 12   0.229199    0.895765   -1.811543  
 16   1.704422    1.792915   -0.131545  
 16  -3.075335    0.571180    1.087378  
 12  -1.320018    2.681918   -0.615147  
 12   1.960670    0.449352    2.102667  
 12  -3.401170   -1.626347    0.146059  
 12   0.876018   -1.805348   -0.851273  
 12  -1.506473   -2.756456   -0.889062 
 14   2.586023   -0.451335    0.924567  
 12  -0.642749    2.181881   -1.908923  
 16  -1.906284    3.817066   -0.669502  
 12  -2.873062   -2.704225   -0.547163 
 16  -4.749176   -1.537792    0.491693  
 12   3.885391    0.087159    0.321512  
 12   4.457055   -0.901355   -0.654010  
 12   5.601399   -1.566176   -0.452201  
 1   -1.599991    2.400039    1.490988  
 1    0.755831   -0.997207    0.901319  
 1    2.818258   -1.364174    1.331940  
 1    0.180387    1.494495    2.659302  
 1   -0.061817   -0.245659    2.661351  
 1    1.090738    0.975507   -2.485893  
 1   -0.366257    0.041514   -2.127655  
 1    1.193944    2.630305   -0.101319  
 1    2.429065    1.419733    1.981785  
 1    2.297025   -0.026103    3.029566  
 1    1.269619   -2.784201   -0.549735  
 1    1.087461   -1.662515   -1.915674  
 1   -1.120531   -3.607368   -1.442473  
 1   -0.050778    3.025197   -2.287571  
 1   -1.434917    2.024218   -2.650623  
 1   -3.527725   -3.522690   -0.841863  
 1   -5.240131   -2.313653    0.157310  
 1    3.614675    1.036610   -0.139672  
 1    4.567656    0.260254    1.160203  
 1     3.897921  -1.044926   -1.576825 
 1    5.998477   -2.255627   -1.190024  
 1    6.195523   -1.431369    0.449056  
6-Acetylmorphine 
Atomic           
No.        X                 Y                   Z 
 12    0.556936   -0.420567    0.462807 
 12    0.697506    1.053772    0.202148 
 12   -0.973818   -0.571201    0.726927 
 12    1.069058   -1.097146   -0.838619 
 12    1.342192   -0.935672    1.701748 
 12   -0.498364    1.707428    0.459029 
 12    1.763932    1.646780   -0.469324 
 12   -1.676812   -1.379672   -0.376365 
 16   -1.521340    0.827063    0.841610 
 12    2.590360   -0.803258   -0.911017 
 12    0.604671   -2.559567   -0.920872 
 12    2.861757   -0.847889    1.538528 
 12   -0.626288    3.072197    0.208004 
 12    2.858515    0.753161   -1.045866 
 12    1.647321    3.027531   -0.719417 
 12   -0.882651   -2.621309   -0.688098 
 16   -2.994081   -1.832822    0.093607 
 14    3.267944   -1.427134    0.247384 
 12    0.485417    3.725847   -0.353663 
 16   -1.841068    3.691342    0.478254 
 12   -4.188879   -1.134155   -0.096101 
 12    4.715103   -1.600239    0.102297 
 12   -4.161563    0.149306   -0.888142 
 16   -5.204731   -1.618829    0.395111 
  1   -1.187405   -1.048115    1.685055  
  1    0.609444   -0.565191   -1.684995  
  1   -1.803559   -0.736563   -1.261096  
  1    3.002372   -1.288704   -1.804040  
  1    1.154013   -3.174647   -0.191187  
  1    1.028174   -0.363508    2.583542  
  1    1.061157   -1.982413    1.873962  
  1    0.861579   -2.983416   -1.906961  
  1    3.195679    0.202766    1.646477   
  1    3.351200   -1.417215    2.337259  
  1    2.964439    0.994461   -2.112650  
  1    3.835538    0.977020   -0.595212  
  1    2.443704    3.560794   -1.230010  
  1   -1.427372   -3.557422   -0.738567  
  1    0.416507    4.791143   -0.560453  
  1   -1.815042    4.640323    0.250463  
  1    5.288096   -0.652457    0.116218  
  1    5.087533   -2.223780    0.922052  
  1    4.930812   -2.113306   -0.840544  
  1   -3.517466    0.888864   -0.402391  
  1   -3.789811   -0.013787   -1.906727  
  1   -5.181796    0.528985   -0.944549  
Morphine 
Atomic   X            Y         Z 
No. 
12     -0.38855200    0.35818300    0.52128300 
12      0.76103500   -0.55427500    0.21567100 
12     -1.23305700    0.39411100   -0.78797100 
12      0.31342700    1.70175600    0.87345200 
12     -1.25876600   -0.08805600    1.72747300 
12      1.96056800    0.07519200    0.50397400 
12      0.67120600   -1.72565600   -0.53357600 
12     -1.80654600   -1.02329000   -0.99158900 
12     -2.07394800    1.65555700   -0.83403500 
16      1.78165800    1.39819300    0.94084300 
12      0.03178900    2.80120700   -0.17151000 
12     -1.91306200   -1.44790300    1.52558800 
12      3.17350400   -0.55805600    0.22581700 
12     -0.66655700   -2.08544900   -1.18289900 
12      1.88533200   -2.37479700   -0.82176000 
14     -2.69840900   -1.48332500    0.20586700 
12     -1.44739200    2.80578200   -0.52765500 
16      0.76279700    2.49654900   -1.40027800 
12      3.10389700   -1.81388900   -0.40828700 
16      4.34414300    0.09654200    0.54165000 
12     -4.02380700   -0.75526800    0.29978000 
1       0.03735600    2.05538000    1.86939400 
1      -2.48231200   -1.05819300   -1.85235900 
1       0.34583300    3.77569400    0.21635100 
1      -2.91506700   -2.46894900    0.01792000 
1      -0.51004300    0.50786900   -1.60747900 
1      -0.62829800   -0.15615500    2.62157200 
1      -2.01138000    0.68384700    1.93190900 
1      -3.10385300    1.64971000   -1.18073700 
1      -1.15995800   -2.23632600    1.45942100 
1      -2.61669600   -1.69678500    2.32409000 
1      -0.50532000   -2.17716800   -2.26462400 
1      -1.03082900   -3.07697600   -0.86775000 
1       1.89971700   -3.29593400   -1.39562500 
1      -1.95704600    3.76111100   -0.58745200 
1       1.72419100    2.50876700   -1.20366200 
1       4.02950100   -2.33260200   -0.64066200 
1       5.13945700   -0.41339900    0.29418300 
1      -4.52610500   -0.80965900   -0.66708200 
1      -4.63380900   -1.24176800    1.06268100 
1      -3.84969200    0.28365100    0.56859100 
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Hydromorphone 
Atomic  
No. X   Y       Z 
12     -0.319932    0.463127    0.539257 
12      0.658444   -0.631827    0.206911 
12     -1.174343    0.625329   -0.745633 
12      0.645454    1.666436    0.810828 
12     -1.211046    0.208305    1.782581 
12      1.959752   -0.211515    0.488939 
12      0.384590   -1.736144   -0.579967 
12     -1.994219   -0.685395   -0.889230 
12     -1.926267    1.966626   -0.750795 
16      2.010194    1.077746    0.951245 
12      0.546475    2.668057   -0.350869 
12     -2.203656   -0.949785    1.577636 
12      3.070692   -1.027839    0.169442 
12     -1.026925   -1.950721   -1.091754 
12      1.501811   -2.541127   -0.946521 
14     -2.866457   -0.858923    0.275519 
12     -0.886023    3.137083   -0.619728 
16      1.518231    3.034450   -1.009058 
12      2.798902   -2.215195   -0.539170 
16      4.305874   -0.585488    0.521039 
12     -4.137569   -1.555928    0.102674 
1      -0.481584    0.643384   -1.599695 
1       0.448622    2.180263    1.755987 
1      -0.580015   -0.010581    2.651290 
1      -1.770018    1.123857    2.009670 
1      -2.640440   -0.622118   -1.769370 
1      -2.484352    2.081946   -1.686036 
1      -2.660325    2.002723    0.060265 
1      -1.667456   -1.912796    1.662518 
1      -2.968165   -0.940401    2.359213 
1      -0.986270   -2.200772   -2.158708 
1      -1.504219   -2.808738   -0.599660 
1       1.351779   -3.426649   -1.555241 
1      -0.847824    3.738253   -1.531353 
1      -1.177636    3.812928    0.196386 
1       3.624606   -2.861041   -0.820235 
1       5.038189   -1.163054    0.224565 
1      -4.638344   -1.200010   -0.800846 
1      -4.000149   -2.648438    0.014420 
1      -4.782443   -1.366874    0.964798 
1     -3.849692    0.283651    0.5685910 
 
Norcodeine 
Atomic  
No.    X         Y          
Z 
12       0.917656    0.131429    0.451603 
12      -0.371432   -0.590365    0.173096 
12       1.793759   -0.127369   -0.808702 
12       0.444485    1.602538    0.613160 
12       1.647569   -0.323700    1.749473 
12      -1.452845    0.259422    0.350436 
12      -0.467682   -1.835215   -0.446798 
12       2.131093   -1.641479   -0.792297 
12       2.945352    0.888644   -0.900654 
16      -1.062540    1.563203    0.690720 
12       0.914951    2.494623   -0.543504 
12       2.155196   -1.766939    1.679144 
12      -2.752247   -0.183292    0.083612 
12       0.810293   -2.506259   -0.947379 
12      -1.770043   -2.286965   -0.723700 
14       2.903046   -1.947273    0.425736 
12       2.386172    2.283996   -0.761083 
16       0.678764    3.897254   -0.249324 
12      -2.889045   -1.487709   -0.428864 
16      -3.794743    0.707069    0.306889 
12      -5.145543    0.275414    0.003696 
 1       1.152764    0.037202   -1.686816 
 1       0.773349    2.051949    1.552515 
 1       2.781928   -1.874630   -1.643395 
 1       0.333408    2.210346   -1.442254 
 1       2.499841    0.347263    1.915262 
 1       0.964011   -0.205801    2.599553 
 1       3.472539    0.773033   -1.863782 
 1       2.828260   -1.967477    2.519933 
 1       1.299733   -2.461351    1.774957 
 1       0.980399   -3.472724   -0.450739 
 1       0.673238   -2.738282   -2.013220 
 1      -1.925706   -3.250271   -1.201070 
 1       3.016876    3.162746   -0.840822 
 1      -0.279109    4.023149   -0.087195 
 1      -3.876788   -1.871737   -0.654578 
 1      -5.434049   -0.590469    0.611920 
 1      -5.777926    1.126540    0.253647 
 1      -5.257782    0.030019   -1.059484 
 1       3.392579   -2.835734    0.371968 
 1       3.703125    0.676283   -0.130266 
Norhydrocodone 
Atomic  
No.         X  Y     Z 
12    0.909031    0.203892    0.532174  
12   -0.343040   -0.533114    0.144504  
12    1.840470    0.112804   -0.702450  
12    0.354899    1.640346    0.800250  
12    1.584628   -0.362550    1.812854  
12   -1.455618    0.238371    0.427775  
12   -0.383766   -1.707383   -0.605749  
12    2.180510   -1.380859   -0.899823  
12    2.958273    1.169937   -0.635935  
16   -1.112212    1.497823    0.945341  
12    0.771110    2.574615   -0.335960  
12    2.055216   -1.802678    1.640040  
12   -2.739331   -0.225199    0.111158  
12    0.922157   -2.267637   -1.169438  
12   -1.663090   -2.178242   -0.943980  
14    2.913805   -1.902140    0.371956  
12    2.279938    2.585611   -0.635818  
16   -0.023934    3.270638   -0.968176  
12   -2.811666   -1.464888   -0.558939  
16   -3.804219    0.568011    0.450090  
12   -5.152661    0.156267    0.070535  
 1    1.231374    0.364656   -1.582700  
 1    0.716685    2.055694    1.747412  
 1    2.426060    0.276804    2.113436  
 1    0.862316   -0.336497    2.636207  
 1    2.910194   -1.517132   -1.704992  
 1    3.578192    1.049221    0.263123  
 1    3.632053    1.089790   -1.496886  
 1    2.667647   -2.151051    2.475408  
 1    1.215600   -2.485995    1.500468  
 1    1.119033   -3.296421   -0.827516  
 1    0.825473   -2.348228   -2.259906  
 1   -1.782843   -3.083686   -1.530747  
 1    2.770244    3.240899    0.096930  
 1    2.391649    3.068882   -1.610223  
 1   -3.781383   -1.859426   -0.835471  
 1   -5.424139   -0.787615    0.555161  
 1   -5.796627    0.956497    0.429041  
 1   -5.240654    0.063689   -1.017052  
 1    3.190044   -2.878151    0.217543  
 1    3.773006   -1.354484    0.501833  
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Codeine 
Atomic    
No.       X          Y                       Z 
12    0.80233100    0.53600500   -0.56175200 
12   -0.21800200   -0.49119600   -0.11323700 
12    1.80292700    0.72881700    0.61170200 
12   -0.11213700    1.75491700   -0.88633600 
12    1.58141700    0.07155900   -1.82286300 
12   -1.48827000   -0.09624700   -0.48542000 
12    0.01584800   -1.60433000    0.69027800 
12    2.40771900   -0.66418500    0.93018300 
12    1.10614300    1.35523200    1.80495900 
16   -1.49194700    1.17697600   -1.07087200 
12   -0.17846800    2.82803200    0.23596700 
12    2.32787800   -1.23830600   -1.58275800 
12   -2.61048500   -0.87775500   -0.18903100 
12    1.38025000   -1.74996500    1.34465900 
12   -1.09600800   -2.40567400    0.99798300 
14    3.20807400   -1.16860900   -0.31791400 
12    0.16632100    2.29057000    1.61016100 
16  -1.44865900    3.50667600    0.21456900 
12   -2.37790700   -2.06229100    0.53808900 
16   -3.83406800   -0.40746300   -0.59987400 
12   -5.03435100   -1.17766200   -0.28648200 
12    4.50007100   -0.41019800   -0.55205400 
1     0.11637700    2.22465500   -1.84350500 
1     3.17009400   -0.57420300    1.71141800 
1     0.56048500    3.60316100   -0.01296500 
1     3.47160400   -2.13542100   -0.09561300 
1     2.62166800    1.39347800    0.29285600 
1     0.88304100   -0.09586800   -2.65099300 
1    2.26833700    0.86519100   -2.14501100 
1     1.38873600    1.03788400    2.80552200 
1     1.62298400   -2.05563900   -1.41642700 
1     2.98939600   -1.50108600   -2.41197400 
1     1.25640800   -1.66381900    2.43248500 
1     1.81592600   -2.75067000    1.19105900 
1    -0.98288800   -3.28668200    1.62221400 
1    -0.34104100    2.77160900    2.44043100 
1    -2.14586500    2.86740200   -0.05340800 
1    -3.21256400   -2.70204800    0.79602600 
1    -5.16532600   -1.27396600    0.79652100 
1    -5.85310100   -0.59972500   -0.71019400 
1    -4.99557100   -2.16762200   -0.75302400 
1     5.06862100   -0.38217000    0.37849400 
1     5.07261500   -0.92999200   -1.32183300 
1     4.27925300    0.60234200   -0.88153900 
Hydrocodone 
Atomic   
No.       X       Y                       Z 
12  -0.68415500    0.35483700    0.49882800  
12   0.48600100   -0.49761700    0.09327700  
12  -1.62006700    0.40525100   -0.73106500  
12   0.02547500    1.70868400    0.82006000  
12  -1.42857200   -0.18597800    1.75014300  
12   1.66998700    0.11767200    0.45663300  
12   0.41453300   -1.62783900   -0.71849200  
12  -2.11661600   -1.04243000   -0.97665800  
12  -2.55347700    1.63001100   -0.65194200  
16   1.45292700    1.37564900    1.04342000  
12  -0.18769900    2.69501700   -0.32963300  
12  -1.98912500   -1.58597000    1.52988100  
12   2.90096600   -0.47592200    0.14946600  
12  -0.92973500   -1.99806200   -1.34432200  
12   1.64126900   -2.22888000   -1.04620300  
14  -2.85856800   -1.64424300    0.25990600  
12  -1.65185900    2.90539000   -0.74857000  
16   0.73692000    3.28385000   -0.89132500  
12   2.85125600   -1.67734600   -0.58954900  
16   4.03909700    0.16495500    0.56507300  
12   5.34232800   -0.37380300    0.18790500  
12  -4.25301200   -1.09156700    0.47547900  
1   -0.33298800    2.16080200    1.75106900  
1   -2.86551200   -1.07298000   -1.77465300  
1   -2.97361700   -2.63965500    0.03657100  
1   -0.98158400    0.58607400   -1.60950300  
1   -0.72356900   -0.24024500    2.58776000  
1   -2.21924700    0.51160800    2.05473600  
1   -3.28693600    1.63790200   -1.46642800  
1   -3.11940000    1.64873200    0.28629900  
1   -1.18001400   -2.30377000    1.37787000  
1   -2.61476400   -1.92423900    2.35953700  
1   -0.82916300   -1.95912800   -2.43721200  
1   -1.21571800   -3.04017700   -1.12658400  
1    1.67509800   -3.11064000   -1.67858100  
1   -1.61992300    3.28223800   -1.77549000  
1   -2.07198100    3.71424300   -0.13512500  
1    3.77734800   -2.16812300   -0.86169900  
1    5.44916500   -0.40932100   -0.90137300  
1    6.06214500    0.32460700    0.60954300  
1    5.49313100   -1.37021400    0.61680600  
1   -4.79916400   -1.13173400   -0.46782700  
1   -4.75760200   -1.70625700    1.22276700  
1   -4.19227600   -0.06433300    0.82340300  
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Appendix 6: Typical TOF-SIMS spectrum of sphingomyelin lipid class in negative 
mode. Characteristic fragments (*) and molecular ions are denoted. 
 
 
 
 
 
 
 
 
 
 
Appendix 7: General TOF-SIMS fragmentation scheme of sulfatide lipid class in 
negative mode 
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Appendix 8: Negative mode SI yields from TOF-SIMS analysis using various primary 
ions of familiar lipid standards. Typical fragments and molecular ions are listed for 
each class 
Negative Mode 
Species 
Mix ST C48H96N2O11S (major component) 
Au3+ Bi3+ Ar1000+ Au400+ 
96.97 HSO4 2.10E-02 1.31E-03 1.77E-02 6.90E-01 
198.98 C4H7SO7 3.30E-04 1.56E-05 1.85E-04 6.00E-03 
256.99 C6H9SO9 9.50E-04 6.27E-06 2.30E-04 1.90E-02 
259.03 C6H11SO9 7.90E-04 6.27E-06 3.90E-04 1.50E-02 
261.00 C6H13SO9 2.40E-03 1.37E-04 4.55E-04 5.60E-02 
281.24 C18:1 2.50E-04 1.45E-06 1.84E-05 2.70E-03 
283.27 C18:0 4.40E-04 1.82E-06 5.34E-05 3.10E-03 
300.04 C8H14NSO9 1.10E-03 1.24E-05 1.97E-04 2.10E-02 
806.5 18:0 Sulfatide 1.80E-04 1.33E-06 1.31E-04 1.10E-02 
862.6 22:0 Sulfatide ---- 5.07E-07 7.74E-05 8.80E-03 
878.7 h22:0 Sulfatide ---- 2.95E-07 3.96E-05 6.30E-03 
888.6 24:1 Sulfatide ---- 9.33E-07 3.98E-04 2.27E-04 
890.7 24:0 Sulfatide 3.00E-04 6.60E-07 2.95E-04 3.40E-02 
906.7 h24:0 Sulfatide ---- 2.51E-07 6.45E-05 1.10E-02 
Species 
SM C39H79N2O6P 
Au3+ Bi3+ Ar1000+ Au400+ 
62.96 PO2 1.50E-02 3.69E-03 2.38E-03 1.20E-01 
78.96 PO3 9.70E-02 2.22E-02 2.70E-02 4.80E-01 
122.99 C2H4PO4 9.50E-03 2.02E-03 2.76E-03 5.50E-02 
168.04 C4H11NPO4 3.10E-03 5.48E-04 6.96E-04 2.40E-02 
255.23 C16:0 4.50E-05 3.72E-05 2.56E-04 ---- 
616.5 C34H67NO6P 4.10E-04 4.11E-05 1.74E-04 3.80E-03 
642.5 C36H69NO6P 7.10E-04 8.97E-05 2.05E-04 6.50E-03 
687.5 C38H76N2PO6 5.40E-04 5.53E-05 6.61E-04 4.50E-02 
701.6 [M-H]- ---- 6.09E-06 3.03E-05 ---- 
Species 
PG C42H80O10P 
Au3+ Bi3+ Ar1000+ Au400+ 
62.96 PO2 8.80E-03 3.60E-03 1.41E-03 4.70E-01 
78.96 PO3 5.50E-02 1.55E-02 2.55E-02 1.60E+00 
96.97 H2PO4 7.10E-03 1.20E-03 1.89E-03 2.90E-01 
153.01 C3H6PO5 6.70E-03 9.62E-04 1.79E-03 1.70E-01 
171.02 C3H8PO6 3.70E-03 3.46E-04 5.06E-04 8.60E-02 
 167 
227.05 C6H12PO7 4.50E-04 8.68E-05 1.33E-04 2.80E-02 
281.24 C18:1 2.50E-03 3.53E-04 9.56E-04 1.60E-01 
283.26 C18:0 4.70E-03 5.69E-04 1.17E-03 9.50E-02 
511.3 C24H48O9P 3.20E-04 7.47E-06 1.79E-05 1.00E-02 
775.5 [M]- 8.70E-04 4.32E-06 2.79E-05 4.30E-02 
Species 
PC C40H80NO8P 
Au3+ Bi3+ Ar1000+ Au400+ 
62.97 PO2 1.30E-02 1.98E-03 2.31E-03 3.30E-01 
78.96 PO3 6.80E-02 1.39E-02 3.08E-02 1.10E+00 
96.98 H2PO4 6.90E-03 1.03E-03 3.32E-03 1.40E-01 
123.00 C2H4PO4 3.20E-03 3.73E-04 1.96E-03 6.10E-02 
224.07 C7H15NPO5 2.30E-04 2.40E-06 4.77E-05 9.90E-03 
255.24 C16:0 7.50E-03 6.11E-04 6.54E-03 9.50E-02 
647.5 C35H67O8P ---- 1.75E-06 4.39E-05 ---- 
673.5 C37H70O8P 1.60E-04 5.05E-06 3.14E-04 5.80E-03 
732.6 [M-H]- ---- 7.80E-07 4.57E-05 ---- 
Species 
PE C33H66NO8P 
Au3+ Bi3+ Ar1000+ Au400+ 
62.96 PO2 1.40E-02 2.77E-03 2.81E-03 3.10E-01 
78.96 PO3 9.30E-02 1.10E-02 2.92E-02 1.00E+00 
96.98 H2PO4 8.30E-03 3.53E-04 2.40E-03 1.10E-01 
122.01 C2H5NPO3 4.30E-03 4.20E-05 8.86E-04 1.50E-02 
140.02 C2H7NPO4 5.40E-03 3.36E-05 7.98E-04 4.20E-02 
196.04 C5H11NPO5 1.20E-03 1.05E-05 1.23E-04 1.10E-02 
227.19 C14:0 1.10E-02 7.23E-05 2.60E-03 8.60E-02 
634.4 [M-H]- 2.30E-03 1.22E-05 2.57E-04 1.60E-02 
 
Appendix 9: Positive mode SI yields from TOF-SIMS analysis using various primary 
ions of familiar lipid standards. Typical fragments and molecular ions are listed for 
each class. 
Positive Mode 
Species 
Mix ST C48H96N2O11S (Major Component) 
Bi3+ Ar1000+ Au400+ 
96.95 HSO4 6.10E-06 3.10E-06 6.60E-03 
105.00 H2SO3Na 1.90E-04 2.80E-05 1.40E-02 
142.94 HSO3NaK 2.60E-05 2.60E-05 4.50E-02 
909.7 [M+H]+ 7.70E-07 1.20E-06 ---- 
Species 
SM C39H79N2O6P 
Bi3+ Ar1000+ Au400+ 
 168 
86.10 C5H12N 1.40E-02 9.50E-03 1.60E-01 
104.12 C5H14NO 8.20E-03 6.70E-03 6.50E-02 
124.98 C2H6PO4 1.60E-03 9.50E-04 6.90E-02 
146.97 C2H5PO4Na 3.10E-04 2.20E-04 2.50E-01 
166.02 C4H9NPO4 1.80E-03 1.00E-03 3.70E-02 
184.07 C5H15NPO4 1.60E-02 1.80E-02 4.00E-01 
206.05 C5H14NPO4Na 2.30E-05 3.20E-06 1.40E-01 
703.6 [M+H]+ 5.80E-07 8.10E-07 ---- 
725.5 [M+Na]+ 1.90E-06 5.40E-06 1.60E-01 
Species 
PG C42H80O10P 
Bi3+ Ar1000+ Au400+ 
125.00 C2H6PO4 1.20E-03 8.90E-04 7.90E-02 
146.98 C2H5PO4Na 3.30E-05 3.50E-05 4.40E-03 
798.5 [M+Na]+ 1.30E-06 2.50E-06 6.30E-03 
821.5 [M+2Na]+ 6.40E-07 1.10E-06 5.40E-02 
Species 
PC C40H80NO8P 
Bi3+ Ar1000+ Au400+ 
86.10 C5H12N 7.60E-03 1.20E-02 2.50E-01 
104.12 C5H14NO 4.00E-03 5.10E-03 4.20E-02 
124.99 C2H6PO4 9.00E-04 1.30E-03 6.40E-02 
146.98 C2H5PO4Na 9.10E-05 2.50E-05 1.20E-01 
184.06 C5H15NPO4 5.60E-03 9.30E-03 1.90E-01 
206.05 C5H14NPO4Na 2.30E-05 3.20E-06 1.70E-02 
734.6 [M+H]+ 3.70E-06 1.10E-05 1.30E-01 
Species 
PE C33H66NO8P 
Bi3+ Ar1000+ Au400+ 
125.00 C2H6PO4 7.90E-05 1.40E-04 3.40E-02 
141.02 C2H8NPO4 2.40E-05 4.60E-05 ---- 
146.99 C2H5PO4Na 2.20E-05 1.40E-05 3.10E-02 
495.4 C31H59O4 5.90E-06 6.70E-05 7.60E-02 
636.5 [M+H]+ 1.10E-06 5.10E-06 3.90E-02 
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Appendix 10: Ratios of of molecular ion to fragment ion secondary ion yields for a) 
Negative mode Au400
4+ impact energy changes b) negative mode Arn cluster size 
experiments and c) positive mode Au400
4+ impact energy experiments. 
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Appendix 11: Ratio of molecular ion to fragment ion secondary ion yield for negative mode 
Au400
4+ impact energy changes. 
 Impact Energy (keV)  M/153 M/281 M/283 M/509 M/511 
320 0.44 0.45 0.68 6.79 9.42 
360 0.45 0.46 0.73 6.04 7.19 
400 0.5 0.54 0.84 6.54 7.24 
440 0.54 0.57 0.9 5.49 9.3 
480 0.5 0.55 0.91 5.7 6.95 
520 0.54 0.56 0.95 5.52 6.12 
 
Appendix 12:. Ratio of molecular ion to fragment ion secondary ion yield for negative 
mode Arn experiments. 
 Arn Cluster Size M/153 M/281 M/283 M/509 M/511 
500 0.02 0.04 0.04 NA NA 
1000 0.02 0.04 0.04 3.30 2.41 
1500 0.03 0.04 0.05 3.50 2.41 
2000 0.06 0.06 0.08 5.37 2.91 
 
Appendix 13:. Ratio of molecular ion to fragment ion secondary ion yield for positive mode 
Au400
4+ impact energy. 
 Impact Energy (keV) M/M+Na M/2M+Na 
280 0.42 2.35 
320 0.45 1.61 
360 0.59 2.35 
400 0.55 1.87 
440 0.60 1.80 
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Appendix 14: Typical fragmentation of PI lipid in negative mode  
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Appendix 15: Typical fragmentation of PE lipid in negative mode 
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Appendix 16: Typical fragmentation of PG lipid in negative mode 
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Appendix 17: Typical fragmentation of PS lipid in negative mode 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Appendix 18: Lipid Analytes and SPLASH Mix analyzed via LC-TIMS-TOF MS with PASEF in negative mode 
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Appendix 18: Identification fragments are typical product ions observed for each lipid class  
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Appendix 19: Lipid profile of Dictyostelium discoideum cells from LC-TIMS-MS/MS negative mode analyses 
 
m/z RT 1/K0 CCS (A2) Lipid ID Identification Fragments 
452.2764 4.43 1.048 217.990 LPE(16:0) 140.02 (HG; C2H7NPO4),   255.23 
(FA; 16:0) 
464.3141 4.39 1.054 219.073 LPE (P-18:0) 140.02 (HG; C2H7NPO4),  403.26 
(18:0p LPA-H2O-H),  421.27 (18:0p 
LPA-H)  
466.3286 4.89 1.064 221.124 LPE(O-18:0) 140.02 (HG; C2H7NPO4), 405.28 
(18:0e LPA-H2O-H), 423.29 (18:0e 
LPA-H) 
476.2778 3.58 1.059 219.954 LPE (18:2) 196.04(HG; C5H11O5PN), 279.23 
(FA; 18:2)  
478.2920 3.95 1.056 219.306 LPE (18:1) 196.04(HG; C5H11O5PN), 281.25 
(FA; 18:1) 
494.2877 2.49 1.090 226.164 LPE (O-20:0) 140.02 (HG; C2H7NPO4), 
196.04(HG; C5H11O5PN), 433.27 
(20:0e LPA-H20-H), 451 (20:0e 
LPA-H) 
506.3234 4.43 1.101 228.301 LPE (20:1) 196.04(HG; C5H11O5PN), 309.28 
(FA:20:1) 
507.2697 3.39 1.092 226.424 LPG (18:2) 152.99 (HG; C3H6PO5 ), 279.23 
(FA; 18:2), 433.28 (18:2 LPA-H) 
522.2816 3.46 1.113 230.604 LPS (18:1) 153.00 (HG;  C3H6PO5), 281.25 
(FA: 18:1), 435.18 (18:1 LPA-H) 
557.3086 3.70 1.149 237.682 LPI(O-16:0) 241.01 (HG; C6H10PO8), 377 (16:0e 
LPA-H20-H)  
567.3645 5.08 1.181 244.198 LPG (22:0) 153.00 (HG;  C3H6PO5), 227.03 
(HG; C6H12PO7), 339.33 (FA; 22:0) 
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571.3232 3.99 1.165 240.851 LPI(16:1) 241.01 (HG; C6H10PO8), 391.26 
(16:0 LPA-H2O-H), 409.27 (16:0 
LPA-H) 
595.2859 3.10 1.179 243.516 LPI (18:2) 223.00 (HG; C6H8PO7), 241.01 
(HG; C6H10PO8), 279.23 (FA; 18:2) 
597.3025 3.44 1.181 243.910 LPI (18:1) 153.00 (HG; C3H6PO5), 223.00 
(HG; C6H8PO7), 241.01 (HG; 
C6H10PO8), 281.25(FA; 18:1), 
315.05 (PI-18:1-H2O-H), 333.06 (PI-
18:1-H) 
630.3765 4.71 1.232 254.144 PE (12:0/16:2) 199.13 (FA; 12:0 ), 251.22(FA; 16:2), 
448.24 (16:2 LPE-H) 
632.3910 4.88 1.238 255.364 PE (12:0/16:1) 199.13 (FA; 12:0 ), 253.32 (FA; 
16:1),  450.26 (16:1 LPE-H), 
644.4645 6.03 1.276 263.098 PE (P-18:2/12:0) 279.23 (FA; 18:2), 364.26 (12:0 LPE-
H2O-H), 382.23 (12:0 LPE-H) 
646.4804 6.22 1.267 261.226 PE (P-18:1/12:0) 281.25 (FA; 18:1), 364.26 (12:0 LPE-
H2O-H), 382.23 (12:0 LPE-H) 
672.5766 6.53 1.301 268.019 PE (15:1/16:1) 196.04(HG; C5H11O5PN), 239.20 
(FA; 15:1), 253.22 (FA; 16:1), 375.22 
(15:1 LPA-H2O-H), 418.27 (15:1 
LPE-H2O-H), 436.28 (15:1 LPE-H) 
676.4200 3.95 1.286 264.899 PS (10:0/18:1) 152.99 (HG; C3H6PO50), 281.25 
(FA;18:1),  
684.4971 6.40 1.316 271.015 PE(P-16:0/17:2) 265.22 (FA; 17:2), 436.28 (P-16:0 
LPE-H) 
686.5123 6.54 1.302 268.117 PE(P-16:0/17:1) 253.22 (FA; 16:1), 267.23 (FA: 17:1), 
281.25 (FA; 18:1), 436 (P-16:0 LPE-
H), 450 (P-17:1 LPE-H) 
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688.5254 6.56 1.311 269.955 PE(P-16:0/17:0) 253.22 (FA;16:1), 269.23 (FA; 17:0), 
281.25 (FA; 18:1), 438.30 (O-16:0 
LPE-H) 
696.4982 6.34 1.330 273.806 PE (P-16:1/18:2) 277.22 (FA; 18:3), 279.23 (FA; 18:2),  
279.23 (FA; 18:2), 434.27 (P-16:1 
LPE-H) 
698.5132 6.55 1.329 273.585 PE(P-16:0/18:2) 196.04(HG; C5H11O5PN), 253.22 
(FA; 16:1), 279.23 (FA; 18:2), 418.27 
(P-16:0 LPE-H2O), 436.28 (P-16:0 
LPE-H) 
700.5251 6.77 1.364 280.774 PE(P-16:0/18:1) 281.25 (FA; 18:1), 418.27 ( (P-16:0 
LPE-H2O), 436.28 (P-16:0 LPE-H) 
6.69 1.328 273.364 PE(O-16:0/18:2) 279.23 (FA:18:2), 420 (O-16:0 LPE-
H2O), 438 (O-16:0 LPE-H) 
702.5438 6.87 1.333 274.378 PE(O-16:0/18:1) 140.02 (HG; C2H7NPO4), 281.25 
(FA; 18:1), 377 (O-16:0 LPA-H2O-
H), 420 (O-16:0 LPE-H2O) ,438 (O-
16:0 LPE-H) 
710.4760 6.05 1.344 276.583 PE(16:2/18:2) 153.00 (HG; C3H6PO5), 251.20 (FA; 
16:2), 279.23 (FA:18:2) 
712.4891 6.00 1.327 273.070 PE(18:2/16:1)/PE(18:1/16:2) 196.04(HG; C5H11O5PN), 251.20 
(FA; 16:2), 253.22 (FA; 16:1), 279.23 
(FA; 18:2), 281.25 (FA; 18:1), 450.26 
(16:1 LPE-H), 476.27 (18:2 LPE-H) 
714.5082 6.46 1.332 274.084 PE(18:2/16:0)/PE(18:1/16:1) 253.(FA 16:1), 255 (FA; 16:0), 279 
(FA; 18:2), 281 (FA; 18:1), 452.28 
(16:0 LPE-H) 
716.5161 5.62 1.337 275.098 PE-(O-19:0/16:1) 253.18 (FA; 16:1), 279.16 (FA; 18:2), 
297.17 (FA; 19:0), 375.13(16:1e 
LPA-H2O-H), 393.24 (16:1e LPA-
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H), 418.27 (16:1e LPE-H2O),  436.28 
( 16:1e  LPE-H) 
716.5161 5.75       295.22 (FA; 19:1), 420.28 (16:0 LPE-
H2O-H), 438.29 (16:0 LPE-H),  
716.5161 6.82 1.339 275.510 PE(18:1/16:0) 281.25  (FA; 18:1), 418.30 (18:1 
LPA-H2O-H), 434.26 (16:0 LPE-
H2O-H), 452 (16:0 LPE-H), 478.30 
(18:1 LPE-H),  
718.4508 4.53 1.336 274.878 PE(18:0/16:0)/PS(12:1/19:0) 225.27 (FA; 12:1),  297.17 (FA; 
19:0), 377.25 (16:0e LPA-H20-H), 
395.25 (16:0e LPA-H), 420.29 (12:1 
LPS-H2O-H), 438.30 (12:1 LPS-H) 
724.5288 6.60 1.354 278.538 PE(18:2/18:1) 279.23 (FA; 18:1), 281.25 (FA;18:1), 
401.25 (18:1 LPA-H2O-H), 444.28 
(18:1 LPE-H2O-H), 462.30 (18:1 
LPE-H) 
726.5440 6.12 1.373 282.432 PE (18:1/18:1) 279.23 (FA; 18:2), 403.26 (18:1 
LPA-H2O-H), 421 (18:1 LPA-H), 
446.30 (18:1 LPE-H2O), 464.31 
(18:1 LPE-H) 
731.5206 6.16 1.373 282.396 PG(O-16:0/18:2) 279.23 (FA; 18:2),  377.25 (16:0e 
LPA-H20-H), 451.28 (16:0 LPG-
H2O-H), 469.29 (16:0-LPG-H) 
733.5350 6.47 1.365 280.737 PG(O-16:0/18:1) 281.25 (FA; 18:1), 377.25 (16:0e 
LPA-H2O-H), 395.26 (16:0e LPA-
H), 451.28 (16:0-LPG-H2O-H), 
469.29 (16:0-LPG-H) 
738.5064 5.61 1.376 282.964 PE (18:2/18:2) 279.23 (FA; 18:2),  433.23 (18:2 
LPA-H), 458.27 (18:2 LPE-H2O-H), 
476.28 (18:2 LPE-H) 
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738.5068 6.32 1.355 278.646 PE (18:2/18:2) 279.23 (FA; 18:2), 458.27 (18:2 LPE-
H2O-H), 476.28 (18:2 LPE-H), 
599.53 
739.4388 4.31 1.342 275.966 PI (O-16:0/12:0) 199.14 (FA; 12:0), 241.01 (HG; 
C6H10PO8),377.25 (16:0e LPA-
H20-H),  395.26 (16:0e LPA-H), 
539.30 (16:0e LPI-H2O-H), 557.31 
(16:0e LPI-H), 577.39 (LPA O-
16:0/12:0) 
740.5285 6.38 1.380 283.772 PE (18:1/18:2) 279.23 (FA; 18:2), 281.25 (FA; 18:1), 
458.27 (18:2 LPE-H2O-H), 476.28 
(18:2 LPE-H), 478.29 (18:1 LPE-H) 
742.5380 6.00 1.385 284.787 PE (18:1/18:1) 281.25 (FA; 18:1), 460.28 (18:1 LPE-
H2O-H), 478.30 (18:1 LPE-H) 
742.5379 6.69 1.365 280.674 PE (18:1/18:1) 281.25 (FA; 18:1),  460.28 (18:1 
LPE-H2O-H), 478.29 (18:1 LPE-H) 
767.4709 4.64 1.373 282.152 PI (O-14:0/18:2) 227.167 (FA;14:0), 279.23 (FA; 
18:2), 377.26 (18:2e LPA-H20-H), 
539.30 (18:2e LPI-H2O-H) 
769.4831 4.45 1.374 282.345 PI (O-14:1/18:2) 229.18 (FA; 14:1), 279.23 (FA; 18:2), 
377.25 (18:2e LPA-H2O-H), 539.30 
(18:2e LPI-H2O0H) 
771.5095 5.97 1.403 288.291 PG (18:1/18:2) 279.23 (FA; 18:2), 281.25 (FA; 18:1), 
415.22 (18:2 LPA-H2O-H), 417.24 
(18:1 LPA-H2O-H), 489.26 (18:2 
LPG-H2O-H), 491.28 (18:1 LPG-
H2O-H), 507.28 (18:2 LPG-H), 
509.28 (18:1 LPG-H) 
807.5375 6.18 1.423 292.172 PI (O-15:0/18:1) 223.00 (HG; C6H7PO7), 241.01 
(HG; C6H10PO8), 259.02 (HG; 
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C6H12PO9), 281.25 (FA; 18:1), 
363.23 (15:0 LPA-H2O-H), 525.28 
(15:0 LPI-H2O-H),  
821.5542 6.30 1.438 295.167 PI(O-16:0/18:1) 241.01 (HG; C6H10PO8), 281.45 
(FA; 18:1), 377.25 (O-16:0 LPA-
H2O-H), 539.30 (18:1p LPI-H2O-H) 
835.5700 6.47 1.451 297.753 PI(16:0/18:1) PI(O-16:0/19:1) 241.01 (HG; C6H10PO8), 255.23 
(FA; 16:0), 281.25 (FA; 18:1), 295.23 
(FA; 19:1), 391.26 (16:0 LPA-H2O-
H), 553.31 (16:0 LPI-H2O-H) 
837.5506 5.86 1.415 290.355 PI(O-16:0/19:0) 241.01 (HG; C6H10PO8), 297.24 
(FA; 19:0), 377.25 (16:0e LPA-H2O-
H), 395.26 (16:0e LPA-H), 539.30 
(16:0e LPI-H2O-H), 557.31 (16:0e 
LPI-H) 
859.5334 6.03 1.464 300.285 PI(18:1/18:2) 279.23 (FA; 18:2), 281.25 (FA; 18:1), 
415.23 (18:2 LPA-H2O-H), 417.24 
(18:1 LPA-H2O-H), 433.24 (18:2 
LPA-H), 577.28 (18:2 LPI-H2O-H), 
579.29 (18:1 LPI-H2O-H), 595.29 
(18:2 LPI-H), 597.30 (18:1 LPI-H) 
868.5939 6.04 1.466 300.646 PI-Cer(t20:0/18:0(2OH)) 241.01 (HG; C5H10PO8), 259.02 
(HG; C6H12PO9) 
896.6229 6.36 1.488 305.009 PI-Cer(t20:0/20:0 
(2OH)/(18:0/22:0) 
241.01 (HG; C5H10PO8), 259.02 
(HG; C6H12PO9) 
938.7565 7.58 1.599 327.539 PE (18:1/32:1)/ PE(18:2/32:0) 241.01 (HG; C5H10PO8), 259.02 
(HG; C6H12PO9) 
940.7709 7.60 1.602 328.143 PE (18:1/32:0) 281.25 (FA; 18:1), 377.25 (16:0e 
LPA-H2O-H), 658.52 (32:0 LPE-
H2O-H), 676.53 (32:0 LPE-H) 
   
1
8
2
 
960.7398 7.50 1.614 330.502 PE(18:1/34:4)/PE(18:2/34:3) 279.23 (FA; 18:2), 281.25 (FA; 18:1), 
680.50 (34:3 LPE-H2O-H), 698.51 
(34:3  LPE-H) 
962.7603 7.62 1.619 331.516  PE(18:1/34:3)/PE(18:2/34:2) 279.23 (FA; 18:2), 281.25 (FA; 18:1), 
698.52 (34:3 LPE-H), 700.53 (34:2  
LPE-H) 
964.7670 7.70 1.621 331.916  PE(18:1/34:2)/PE(18:2/34:1) 279 (FA; 18:2), 281 (FA;18:1),  
659.49 (34:1 LPA-H2O-H) 682.51 
(34:2  LPE-H2O-H), 700.53 (34:2  
LPE-H) 
976.7316 7.37 1.624 332.472 PS(18:2/32:2)/PS(18:1/32:3) 279.23 (FA; 18:2), 281.25 (FA; 18:1), 
391.23 (16:0 LPA-H2O-H), 415.23 
(18:2 LPA-H2O-H), 433.23 (18:2 
LPA-H), 694.48 (32:4 LPS-H2O-H), 
714.51 (32:3 LPS-H),  738.51 (34:5 
LPS-H) 
988.7718 7.80 1.644 336.510 PS(P-18:2/34:3)/PS(P-18:1/34:4) 279.25 (FA; 18:2), 281.25 (FA;18:1), 
401.24  (18:2 LPA-H2O-H), 706.51 
(34:4 LPS-H2O-H), 724.52 (34:4 
LPS-H) 
990.7848 7.80 1.644 336.500 PS(P-18:2/34:4)/PS(P-18:1/34:5) 279.23 (FA;18:2), 281.25 (FA; 18:1), 
401.24 (18:2 LPA-H2O-H), 403.26 
(18:1 LPA-H2O-H), 421.27 (18:1 
LPA-H), 423.42(18:2 LPA-H), 
708.54 (34:4 LPS-H2O-H), 726.54 
(34:4 LPS-H) 
1000.7357 7.19 1.640 335.636 PS (18:2/34:5) 279.23 (FA; 18:2), 415.23 (18:2 
LPA-H2O-H), 720.49 (34:5 LPS-
H2O-H), 738.50 (34:5 LPS-H) 
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1002.7501 7.38 1.642 336.036 PI(31:6/18:2) 279.23 (FA; 18:2), 281.25 (FA; 18:1),   
415.23 (18:1 LPA-H2O-H), 417.24 
(18:2 LPA-H2O-H), 722.52 (34:4 
LPS-H2O-H), 738.53 (34:5 LPS-H), 
740.54 (34:4 LPS-H) 
1031.7269 6.87 1.654 338.362 PI (18:2/31:6) 279.23 (FA; 18:2), 415.23 (18:2 
LPA-H2O-H),  433.24 (18:2 LPA-H), 
751.49 (31:6 LPI-H2O-H), 769.50 
(31:6 LPI-H) 
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